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General introduction
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The kidneys are essential in maintaining the body’s internal balance of water, acid me-
tabolism, hormones and minerals. Many diseases can result in kidney failure, requiring 
short term or long lasting kidney replacement therapy, like dialyses.
Kidney transplantation is the best treatment for irreversible end stage renal disease 
(1). The first unsuccessful deceased donor kidney transplantation was performed by a 
Russian surgeon Yuri Voronoy in 1933, using the femoral artery and vein of the recipi-
ent. In the 1950s a group of French transplant surgeons (René Küss, Charles Dubost and 
Marceau Servelle) were the first who used the extraperitoneal renal transplantation 
procedure which is commonly used nowadays - called the ‘Küss-procedure’.
From the 1970s adequate immunosuppressive therapy evolved and this enabled kid-
ney transplantation on a larger scale. Since then many studies demonstrated a clear 
benefit for transplant recipients and in addition, kidney transplantation also results in a 
financial benefit for society (2). Nowadays, an average of 950 kidney transplantations are 
performed in the Netherlands each year, leading to a decrease on the Dutch waiting list 
from 883 patients in 2011 to 576 patients in 2015.
The success of kidney transplantation may be hampered by immunological problems, 
including vascular or cellular rejection, and recurrence of disease in the transplant. Of 
course, a patient may also be confronted with surgical complications that may lead to 
morbidity, graft loss and even mortality (3, 4). Preventing these surgical complications 
is a prerequisite for long term success and minimizing their incidence is one of the chal-
lenges in kidney transplantation.
Therefore, the aim of the studies presented in this thesis is to optimize outcome of 
kidney transplantation by reducing surgical complications.
Urological complications
After the vascular anastomoses of the renal artery and vein on the external iliac vessels 
the ureteroneocystostomy is performed. This anastomosis between transplant ureter 
and bladder may be complicated by urinary leakage or ureteral stenosis (5). There are 
two types of ureteroneocystostomies (intravesical and extravesical). A previously con-
ducted randomized controlled trial performed at the Erasmus MC has proven that both 
techniques are alike in the overall number of urological complications. However, the 
extravesical technique is associated with fewer urinary tract infections and therefore 
recommended (6). As the use of a ureteral stent is still under debate (7) we studied in 
chapter 2 the benefits of the use or non-use of ureteral stents in a randomized controlled 
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trial. In addition, in chapter 3 the outcome of two diff erent external ureteral stents are 
compared as measured by the number of complications.
Several risk factors related to the development 
of urological complications after transplanta-
tion have been well established, including male 
gender for donor or recipient, pre-emptive 
transplantation and arterial reconstructions 
of multiple arteries of the kidney graft (8, 9). 
The infl uence of ureteral length of the graft on 
the number of urological complications is still 
unknown and subject of research in chapter 4.
Percutaneous nephrostomy placement (PCN) 
is the initial step in the treatment of urological 
complications, either due to leakage or stenosis. 
The urinary fl ow is deviated from the uretero-
neocystostomy and anastomotic healing may 
be supported. If the anastomosis fails to heal 
the next step in the treatment schedule may 
include surgical re-intervention, or in case of 
stenosis antegrade balloon dilatation, a minimal 
invasive treatment option for ureteral strictures 
(10). The outcome of this latter technique has 
not been studied in detail. In chapter 5, we 
present a case series of 50 transplant recipients 
who are treated by balloon dilatation in the Am-
sterdam Medical Center (AMC) and the Erasmus 
Medical Center.
Infections are a common problem in 
patients receiving immunosuppressive 
treatment after transplantation. Uri-
nary tract infections (UTI) after kidney 
transplantation are reported up to 38% (11). Analysis of risk factors associated with the 
development of UTI may help to reduce urinary tract related complications. Therefore, 
in chapter 6 we conducted a detailed study of 417 kidney transplant recipients and tried 
to defi ne the risk factors related to UTI.
Kidney
Ureter
Bladder
Urethra
Ureteroneocystostomy
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Guided by the outcome of the studies performed we will propose a new protocol for 
external vs. internal (double J) stenting in chapter 7.
Other surgical complications
In addition to urological complications, other surgical problems may occur after kidney 
transplantation, such as bleeding, vascular thrombosis and wound infections. A less 
common complication after kidney transplantation is incisional hernia, although it is 
one of the most frequent postoperative complications after regular abdominal surgery. 
The incidence in regular abdominal surgery varies between 11 and 20% in the general 
population and has great impact on the health related quality of life and body image 
(12-16). Known risk factors for development of incisional hernia are obesity, aneurysm 
of the abdominal aorta, wound infections and immunosuppressive therapy (15-17). 
Hence, it is suggested that transplant recipients may have an increased risk to develop 
incisional hernia due to the use of postoperative immunosuppressive therapy. In chap-
ter 8, the incidence, risk factors and treatment options of incisional hernia after kidney 
transplantation are documented.
Retransplantation may be considered if a kidney transplant fails. In 2015, 152 out of 576 
patients (26%) on the Dutch kidney transplant waiting list, awaited a retransplant. If a re-
transplantation must be performed, the use of the contralateral iliac fossa is advocated. 
However, in case of a third or even fourth retransplant, it is unavoidable to explore an 
iliac fossa that has already been dissected for the previous implantation and for removal 
of the non-functioning graft. In chapter 9, the surgical challenges of a retransplantation 
in the ipsilateral fossa are described.
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Abstract
Stenting of the ureteral anastomosis in kidney transplantation is still open for discus-
sion. In living donor kidney transplantation, we tested the hypothesis if omitting a stent 
is as effective as the use of a stent regarding urological complications. In this random-
ized controlled trial (SPLINT), eligible patients who received a living donor kidney 
transplantation in the Erasmus University Medical Center were included consecutively 
between April 2014 and March 2017. Exclusion criteria were lack of informed consent, 
age (< 18years), abnormalities of the urinary tract system, primary focal segmental glo-
merulosclerosis (FSGS) and participation in another ongoing clinical trial. Two-hundred 
patients were randomized for suprapubic externalized single J stent placement (N=100) 
or no stent placement (N=100). Primary outcome was defined as the number of percuta-
neous nephrostomy placements (PCN) up to 1 month postoperatively. In total 124 males 
and 76 females were included, with a mean age of 54 years; 101 patients were random-
ized in the stent group and 99 patients in the no stent group. Baseline characteristics 
were comparable in both groups. In the no stent group, there were significantly more 
PCN placements, 18% vs 4%, P=0.001, more urinary leakages, 12% vs 0%, P<0.001 and 
surgical re-interventions due to urological complications 7% vs 1%, P=0.028. In the stent 
group, there were more patients with haematuria, 76% vs 49%, P<0.001, graft rejection, 
36% vs 21%, P=0.024 and prolonged hospital stay, 13 vs 10 days, P<0.001. Mean GFR at 
day 7, 14, 21 and 1 month after transplantation was equal in both groups. In multivariate 
risk factor analyses, the variables that were independently related to PCN placement, 
were no stent placement (OR 7.67, 95%CI 2.33-25.20), history of smoking (OR 3.37, 
95%CI 1.05-10.81) and first warm ischemia time (OR 0.56, 95%CI 0.34-0.93). Although 
stent placement may increase postoperative hematuria and prolong hospital stay, 
stenting should be advocated in living donor kidney transplantation. Stent placement 
significantly reduced the number of PCN placements, urinary leakages and surgical re-
interventions due to urological complications.
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Introduction
Kidney transplantation is the only treatment offering long-term benefit to patients with 
chronic kidney failure. Urological complications after kidney transplantation, such as 
urinary leakage and ureteral strictures, are associated with significant morbidity, surgi-
cal and radiological interventions, prolonged hospital stay and even mortality. Most 
urological complications are related to the ureteroneocystostomy and are treated by 
percutaneous nephrostomy (PCN) placement1,2.
It has been suggested that standard use of a ureteral stent in kidney transplantation 
may diminish the risk of urological complications. However, stent placement has disad-
vantages as well and the role of ureteral stents in living donor kidney transplantation 
is still not well defined. Stent related complications may include infection, obstruction, 
stent migration, breakage, stone formation, haematuria, and secondary ureter obstruc-
tion3,4. Currently, there are no well-defined evidence based arguments that favour stent 
placement.
In this SPLINT-trial (Stent PLacement IN living donor kidney Transplantation) the hypoth-
esis will be tested if omitting a ureteral stent in kidney transplantation is as effective or 
even reduces the number of urological complications without stent related problems. 
This study has a follow up of 1 year, including analyses concerning cost-effectiveness 
and quality of life. This is a preliminary report with only the clinical outcome of events 
that occurred within 1 month after transplantation.
Methods
Study design
In this randomized controlled trial, we included all patients who received a living do-
nor kidney transplantation in the Erasmus University Medical Center, Rotterdam, the 
Netherlands, between April 2014 and March 2017. Exclusion criteria were no informed 
consent, age (< 18years), duplicated ureter system of the donor kidney, patients with 
a reconstructed urinary tract or conduit after total or partial cystectomy, patients with 
bladder dysfunction that requires continuous or intermittent catheterization. Patients 
with primary focal segmental glomerulosclerosis (FSGS) and residual urine production 
were also excluded. Because FSGS is known for its quick recurrence in the kidney graft 
and a first sign is proteinuria. With an externalized stent, we can distinguish between 
proteinuria of the transplant kidney and the native kidneys. Furthermore, we excluded 
recipients that were included into another ongoing clinical trial. After intubation in 
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the operating room, we randomized 200 recipients for either stent placement (N=100, 
Teleflex, suprapubic externalized single J stent, 7fr) or no stent placement (N=100). Ran-
domization was performed after intubation in the operation room by a envelop system, 
randomized by an independent statistician at the Erasmus Medical Center. Due to the 
use of an externalized stent, blinding was not possible. The Medical Ethical Committee 
of the Erasmus University Medical Center approved the trial protocol (MEC-2013-196) 
and the study was registered at the (Dutch) Netherlands Trial Register (NTR4498).
Surgical technique
Donor nephrectomy was performed with either a fully laparoscopic, a robot assisted 
of hand assisted approach. In recipients, an extraperitoneal approach of the iliac fossa 
was performed in all patients. Firstly, the renal artery was anastomosed to the external 
iliac artery and the renal vein to external iliac vein, followed by an extravesical uretero-
neocystostomy described by Lich-Gregoir5,6. The detrusor muscle was closed over the 
anastomosis by one or two interrupted absorbable sutures to create a sub-mucosal 
tunnel with an anti-reflux mechanism. When randomized to stent placement, a 7fr 
suprapubic externalized single J stent (Teleflex) was used and removed 9 days postop-
eratively. A transurethral urinary bladder catheter was standard care in all patients and 
was removed after 7 days.
Power calculation
The SPLINT-trial was designed as a non-inferiority study and powered to demonstrate 
that omitting a stent does not lead to a relevant increased complications rate, i.e. rate of 
required PCN drainage. To show that the increase of patients without a stent requiring 
a PCN is at most 5% (non-inferiority margin), 96 patients per arm were required (one-
side alpha= 0.025, power=90%). In this calculation, it was assumed that in case of stent 
placement, 20% of the patients need a PCN1, while in case of no stent placement this 
percentage equals 9%2. To allow for a few non-evaluable cases, 100 patients per arm 
were randomized.
Definitions
Baseline data of the recipients included gender, age, ASA classification, number of previ-
ous transplantations, body mass index (BMI), warm and cold ischemia time, duration of 
surgery, per-operative blood loss, pre-emptive transplantation (prior to start dialysis), 
rejection <1 month, surgical re-interventions < 1 month after kidney transplantation 
(KT) and length of hospital stay. Our primary outcome was PCN placement within 1 
month. Urinary leakage, (detected by a MAG-3 scan or proven by chemistry samples 
in case of extensive fluid production of the wound or by the drain) or a rise in serum 
creatinine level combined with a hydronephrosis on ultrasound, indicated PCN place-
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ment. Our secondary outcome was graft function measured using Glomerular filtration 
rate (GFR), haematuria (defined as macroscopic haematuria during hospital admission), 
urinary tract infection (UTI) and rejection. UTI was scored when there as a urinary culture 
with a bacterium of ≥ 10^5 CFU/mL which was treated with antibiotics. Rejection was 
scored if patients received anti-rejection treatment (methylprednisolone intravenous, 
IVIG, alemtuzumab, r-ATG). History of smoking included current or past smokers.
Immunosuppressive treatment
Immunosuppressive treatment consisted of basiliximab intravenous on the day of sur-
gery and day 4 after transplantation. Postoperative immunosuppression consisted of 
tacrolimus, mycophenolate mofetil and prednisolone. The prednisone was tapered off 
to be discontinued at 4 months after transplantation.
Statistical analysis
All analyses were conducted using IBM SPSS Statistics for Windows (version 21.0. Ar-
monk, NY: IBM Corp, USA). A p-value of <0.05 (two-sided) was considered statistically 
significant. Continuous variables with normal distribution are presented as means with 
standard deviation and analyzed using the independent t test. Skewed distributed 
variables are presented as median (range) and analyzed using the Mann-Whitney U test. 
Categorical variables were presented as numbers with percentages and were analysed 
using Chi-square test. We performed multivariate analysis using logistic regression and 
included covariates with p-values <0.1 in univariate analysis. The analysis was two-tailed 
and results were presented as odds-ratios (OR) with 95% confidence intervals (95% CI).
Results
Baseline characteristics
Between April 2014 and March 2017, 200 patients were included in the SPLINT-trial. In 
one patient, the randomisation was overruled by the surgeon, since he judged it as nec-
essary to place a stent because of difficulties perioperative. We included 99 patients in 
the no stent group and 101 patients in the stent group. In total 124 males and 76 females 
were included, mean age was 54 years. Baseline characteristics were comparable in both 
groups (gender, age, ASA classification, number of previous KT, donor nephrectomy 
technique, BMI, history of smoking, pre-emptive transplantation, ischemia times, ure-
teral length and residual urinary production of recipients). Table 1.
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Urological complications
In the no stent group, 18 patients received a PCN within 1 month after transplantation. 
Of this group, 11 patients received a PCN due to urinary leakage. Six urinary leakages 
resolved without further interventions, 3 patients needed a surgical re-intervention 
due to the urinary leakage and 2 patients underwent both antegrade balloon dilata-
tion, as well as a surgical re-intervention. Note that 1 patient in the no stent group with 
urinary leakage did not receive a PCN, but underwent direct surgical repair. In the no 
stent group, 7 patients received a PCN due to hydronephrosis. One of these patients un-
derwent balloon dilatation, the others resolved without any intervention. One patient 
in the no stent group with hydronephrosis due to a blood clot in the ureter also did 
not receive a PCN and underwent direct surgical repair. In the stent group, 4 patients 
Table 1. Baseline characteristics
Characteristic Total (200) No Stent (99) Stent (101) P-value
Gender recipient N (%) 0.857
M 124 (62) 62 (63) 62 (61)  
F 76 (38) 37 (37) 39 (39)  
Age recipient in years mean ± SD 54±13 55±13 52±14 0.174
Gender donor N (%) 0.158
M 81 (41) 45 (45) 36 (36)  
F 119 (59) 54 (54) 65 (64)  
Age donor in years mean ± SD 54±12 54±12 53±13 0.599
ASA N (%) 0.371
2 28 (14) 11 (11) 17 (17)  
3 164 (82) 85 (86) 79 (78)  
4 8 (4) 3 (3) 5 (5)  
Number KT N (%) 0.259
1 173 (86) 89 (90) 84 (83)  
2 19 (10) 6 (6) 13 (13)  
3 8 (4) 4 (4) 4 (4)  
Technique laparoscopic N (%) 123 (62) 60 (61) 63 (62) 0.797
BMI recipient mean ± SD 27±5 28±5 27±5 0.368
History of smoking N (%) 123 (61) 59 (60) 64 (63) 0.584
Pre-emptive KT N (%) 102 (51) 47 (47) 55 (55) 0.323
Residual urinary production N (%) 172 (86) 82 (83) 90 (89) 0.201
Ureteral length in cm; mean ± SD 9±2 9±2 9±2 0.285
First warm ischemia time in minutes; mean ± SD 3±1 3±1 3±2 0.190
Cold ischemia time in minutes; mean ± SD 140±29 142±31 139±27 0.374
Second warm ischemia time in minutes; mean ± SD 20±7 20±7 20±8 0.885
M, male; F, female; KT, kidney transplantation; SD, standard deviation; BMI, body mass index; N, number.
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received a PCN within 1 month after transplantation, all due to hydronephrosis. One 
patient underwent balloon dilatation and another patient balloon dilatation followed 
by a surgical re-intervention. There were significantly more PCN placement in the no 
stent group, 18% vs 4% (P=0.001). There were significantly more urinary leakages in the 
no stent group, 12% vs 0% (P<0.001) and significantly more surgical re-interventions 
due to urological complications 7% vs 1 %, (P=0.028). The number of PCN placed due to 
hydronephrosis was not different. Details are depicted in figure 1 and table 2.
Table 2. Urological complications
Characteristic Total 
(200)
No Stent 
(99)
Stent 
(101)
P-value
PCN placement < 1 month N (%) 22 (11) 18 (18) 4 (4) 0.001
Urinary leakage < 1 month N (%) 11 (6) 12 (12) 0 (0) <0.001
Hydronephrosis < 1 month N (%) 12 (6) 8 (8) 4 (4) 0.220
Surgical re-intervention due to urological complications N (%) 8 (4) 7 (7) 1 (1) 0.028
Antegrade balloon dilatation N (%) 5 (3) 3 (3) 2 (2) 0.634
PCN, percutaneous nephrostomy placement; N, number.
Figure 1. Flowchart SPLINT-trial
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Overall outcome
There were no differences between the stent and no stent group regarding duration 
of surgery, blood loss, overall surgical re-intervention within 1 months, urinary tract 
infections, urosepsis, wound infections and readmissions within 1 month after trans-
plantation. Duration of ureteral anastomosis with stent placement was 17 min vs 12 
minutes in the no stent group (P<0.001). In the stent group, there were significantly 
more patients with macroscopic haematuria, 76% vs 49% (P<0.001). In addition, in the 
stent group there were more patients treated because of graft rejection within 1 month 
after transplantation, 36% vs 21%, (P=0.024) and the total length of hospital stay was 
significantly higher with a mean of 13 vs 10 days (P<0.001). Table 3.
Graft outcome
Mean GFR at day 7, day 14, day 21 and 1 month after transplantation was equal in both 
groups as depicted in table 4.
Table 3. Overall outcome
Characteristic Total (200) No Stent (99) Stent (101) P-value
Duration of surgery in minutes; mean ± SD 116±36 113±39 119±33 0.281
Blood loss in mL; median (range) 150 (0-2000) 150 (0-2000) 150 (0-1300) 0.352
Surgical re-intervention < 1 month N (%) 20 (10) 10 (10) 10 (10) 0.962
Hematuria N (%) 126 (63) 49 (49) 77 (76) <0.001
UTI N (%) 45 (23) 25 (25) 20 (20) 0.356
Urosepsis N (%) 8 (4) 4 (4) 4 (4) 0.977
Wound infection N (%) 22 (11) 14 (14) 8 (8) 0.160
Rejection <1-month N (%) 57 (29) 21 (21) 36 (36) 0.024
Biopsy proven rejection < 1-month N (%) 47 (23) 13 (13) 34 (34) 0.001
Total length of hospital stay (days) mean ± SD 11±5 10±4 13±6 <0.001
Readmission <1-month N (%) 34 (17) 21 (21) 13 (13) 0.116
SD, standard deviation; N, number; UTI, urinary tract infection
Table 4. Graft outcome
Characteristic No stent (99) Stent (101) P-value
GFR mL/min 7 days after KT mean ± SD 41 ± 15 42 ± 19 0.880
GFR mL/min 14 days after KT mean ± SD 46 ± 15 46 ± 17 0.493
GFR mL/min 21 days after KT mean ± SD 48 ± 14 47 ± 16 0.814
GFR mL/min 1 month after KT mean ± SD 47 ± 14 47 ± 16 0.342
GFR, Glomerular Filtration Rate; KT, kidney transplantation; SD, standard deviation
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Risk factor analyses PCN placement
In a univariate risk factor analysis for PCN placement, stent placement, history of smok-
ing and the first warm ischemia time had P-values <0.1. Table 5. These variables were 
included in our multivariate analysis, which showed that no stent placement (OR 7.67, 
95%CI 2.33-25.20), history of smoking (OR 3.37, 95%CI 1.05-10.81) and first warm isch-
emia time (OR 0.56, 95%CI 0.34-0.93) were independently related to PCN placements. 
Table 6.
Table 5. Risk factors for PCN placement
Characteristic No PCN (178) PCN (22) P-value
Gender recipient N (%) 0.527
M 109 (61) 15 (68)  
F 69 (39) 7 (32)  
Stent placement N (%) 97 (55) 4 (18) 0.001
Age recipient in years mean ± SD 53±13 56±16 0.357
Gender donor N (%) 0.675
M 73 (41) 8 (36)  
F 105 (59) 14 (64)  
Age donor in years mean ± SD 53±12 56±14 0.330
ASA N (%) 0.778
2 26 (15) 2 (9)  
3 145 (81) 19 (86)  
4 7 (4) 1 (5)  
Number KT N (%) 0.592
1 153 (86) 20 (91)  
2 17 (10) 2 (9)  
3 8 (4) 0 (0)  
Technique laparoscopic N (%) 107 (60) 16 (73) 0.251
BMI recipient; mean ± SD 27±5 28±6 0.238
History of smoking N (%) 105 (59) 18 (82) 0.038
Pre-emptive KT N (%) 92 (52) 10 (46) 0.581
Residual urinary production N (%) 155 (87) 17 (77) 0.211
Ureteral length in cm; mean ± SD 9±2 9±2 0.794
First warm ischemia in minutes; mean ± SD 3.2±1.4 2.7±0.7 0.084
Rejection <1month N (%) 52 (29) 5 (23) 0.525
Cold ischemia time in minutes; mean ± SD 140±29 142±28 0.797
Second warm ischemia time in minutes; mean ± SD 19.4±7.4 20.9±5.8 0.350
Duration of surgery in minutes; mean ± SD 116±37 116±28 0.974
Blood loss in mL; median (range) 150 (0-2000) 200 (20-575) 0.161
M, male; F, female; KT, kidney transplantation; SD, standard deviation; BMI, body mass index; N, number; 
PCN, percutaneous nephrostomy placement.
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Discussion
These are the preliminary data of the SPLINT trial, a randomized controlled trial in 
living donor kidney transplantation, which investigated the influence of stent vs no 
stent placement on the number of urological complications. There were significantly 
more PCN placements, urinary leakages and surgical re-interventions due to urological 
complications in the no stent group. In the stent group, there was significantly more 
haematuria and graft rejection. Furthermore, the total length of hospital stay was higher 
in the stent group with a mean of 13 vs 10 days. The variables that were independently 
related to PCN placement, were no stent placement (OR 7.67), history of smoking (OR 
3.37) and first warm ischemia time (OR 0.56).
Before conducting this trial, there were no well-defined evidence based arguments that 
favoured stent placement. In total 5 randomized controlled trials7-11 on stent placement 
have been reported previously. These studies differ in study design regarding living and 
deceased donation, intravesical or extravesical anastomosis and type of stent. Stent-
ing seemed to be in favour, but it remained open for discussion whether this should 
be on routine basis or only on strictly defined criteria. A Cochrane review on this topic 
supports the use of ureteral stents in selected recipients, but without a statement on 
routine stenting, type of stent and timing of stent removal12.
We first studied if the type of anastomosis (extravesical vs intravesical) was a risk factor 
for PCN placement 13. There was no difference in the number of PCN placement between 
the intra and extravesical anastomosis (20% vs 20%), however the number of urinary 
tract infections was lower in the extravesical group. The extravesical anastomosis has its 
place in our standard care nowadays.
With these preliminary results of the SPLINT trial, we are convinced that stent placement 
with an extravesical anastomosis does reduce the number of urological complications 
significantly. Within 1 month after transplantation, there were 4% PCN placements in the 
stented extravesical anastomosis group. This seems to be considerably lower compared 
to the previously published data (20%) of the INEX trial. Of course, we cannot state yet 
Table 6. Multivariate risk factor analysis
Risk factor Odds ratio 95% CI P-value
History of smoking 3.37 1.05-10.81 0.041
No stent 7.67 2.33-25.20 0.001
First warm ischemia time 0.56 0.34-0.93 0.024
CI, 95% Confidence Intervals
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whether this difference can be explained by the follow up of 3 months in the INEX vs 1 
month in this preliminary report of the SPLINT trial.
Although stent placement significantly increases the duration of ureteral anastomosis 
with 5 minutes, it did not influence the total duration of surgery. The total length of 
hospital stay is significantly higher in the stent group. However, there were 21 patients 
who needed to be readmitted within 1 month in the no stent group and only 13 in 
the stent group (P=0.116). The analysis of readmissions within 1 year will provide more 
information concerning this subject.
A remarkable finding was the significantly higher number of rejections in the stent 
group, 36% vs 21%, P=0.024. These were the patient who received anti-rejection treat-
ment (methylprednisolone intravenous, IVIG, alemtuzumab, r-ATG) within 1 month after 
transplantation. We did not find any explanation for this finding other than coincidence. 
Patients with stents are hospitalized longer, maybe rejections are detected faster during 
clinical stay than in outpatient visits. Also, urine production can be monitored accu-
rately with the external stent, possibly inducing a low threshold for biopsy. However, 
the number of biopsy proven rejections were significantly higher in the stent group as 
well, 34% vs 13% (P=0.001). We do not believe that the material used in stents induces 
more rejection.
We identified three risk factors for PCN placement; no stent placement, history of smok-
ing and the first warm ischemia time. The risk factor of the first warm ischemia time 
should be interpreted with caution, as the difference between both groups is only 0.5 
minute (30 seconds) and is not significant in univariate analyse. Furthermore, if warm 
ischemia time would influence outcome, a significant P-value for the second warm 
ischemia time would also have been expected.
There are a few limitations to this study. These are the preliminary results of a trial with 
a total follow up of 1 year after transplantation. We have only included events (PCN, re-
admissions and re-interventions) which occurred within 1 month after transplantation. 
Late events are not included yet and can still change the definitive outcome of this trial. 
Furthermore, the results concerning the cost-effectiveness and quality of life analyses 
are left out now as well. Besides, the suprapubic externalized type of stent used in this 
trial is not a commonly used stent. Most transplant centers use a double J stent and in 
literature the double J stent also has minor urological complications. A retrospective 
study by Vogel et al. including 76 patients with 43 externalized stents and 33 double 
J stents have reported an incidence of leakage of the ureteroneocystostomy of 13.9% 
in the externalized stent group compared to 0% in the double J group. Furthermore, 
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they found a 2 day reduction of hospital stay with an internal stent 14. Gomes et al. also 
retrospectively reviewed the use of external, internal stents and no stent in 2061 kidney 
transplant recipients. In their cohort, urological complications occurred in 17.3% in 
the group with external stents, 8.4% in patients that did not receive a stent, and 5.4% 
in kidney transplant recipients in whom a double J stent was placed (P < .0005)15. The 
authors even state: ”use of an external catheter which was associated with a high rate 
of UC, should be avoided”. Guleria et al. also reduced their urological complications by 
changing their technique from a non-stented (7.7%) to a double J stented (for a pe-
riod of 6 weeks) ureteroneocystostomy (3.8%) 16. Unfortunately, all these studies have 
a retrospective design and no prospective randomized controlled trials are available. 
Therefore, we suggest a new trial that will investigate whether single J or double J stent-
ing is superior in reducing the number of urological complications.
We conclude that although stent placement increases postoperative hematuria and total 
length of hospital stay, it should be advocated during living donor kidney transplanta-
tion based on these preliminary data. Stent placement significantly reduced the number 
of PCN placements, urinary leakage and surgical re-interventions due to urological 
complications. Further research concerning the type of stent should be conducted.
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Abstract
The aim of this study was to evaluate the effects of 2 types of external ureteral stents on 
the number of urological complications after kidney transplant. Data were retrospec-
tively collected from 366 consecutive transplants performed between January 2013 
and January 2015 in our hospital, in which an external ureteral stent was placed during 
surgery and removed after 9 days. Urological complications were defined as urinary 
leakage or ureteral stenosis requiring percutaneous nephrostomy placement. A total of 
197 patients received a straight stent with 2 larger side holes (type A; 8F “Covidien” tube, 
Covidien, Dublin, Ireland) and 169 patients received a single J stent with 7 smaller side 
holes (type B; 7F “Teleflex” single J stent; Teleflex Medical, Athlone, Ireland). We found 
a significantly higher number of percutaneous nephrostomy placements with type 
A stents, with 34 (17%) versus 16 (9%) in type B (P = 0.030). Reason for percutaneous 
nephrostomy placement, occurrence of stent dysfunction, and need for early removal 
(< 8 days) were equal in both groups (P = 0.397), whereas incidence of rejection and 
urinary tract infection were higher in type B stent group. Patient and graft survival did 
not differ between the groups. Use of the type B stent was associated with less urologi-
cal complications compared with the type A stent.
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Introduction
Kidney transplant is the best and most cost-effective treatment for patients with end-
stage renal disease, improving both quantity and quality of life for recipients.1 Urological 
complications, such as urinary leakage and ureteral strictures, can compromise graft 
function and are associated with patient morbidity, mortality, prolonged hospital stay, 
and reinterventions.2,3 Complication rates due to failure of the ureteroneocystostomy 
are reported to be up to 30% and usually occur within the first 3 months after trans-
plant.4,5 Radiological or surgical reinterventions are often needed if urological complica-
tions do not dissolve spontaneously. A previously conducted randomized controlled 
trial showed that 20% of all kidney recipients required placement of a percutaneous 
nephrostomy (PCN) drain.6 Moreover, 5% of this cohort needed ureteral reintervention, 
including balloon dilatation or surgical revision of the ureteroneocystostomy.6
Several factors are presumed to influence the number of urological complications after 
kidney transplant, including preemptive transplants, male sex of recipient and donor, 
and the presence of multiple renal arteries.7,8 Furthermore, ureteric stenting in renal 
transplant is still debated. Some studies suggest that prophylactic ureteral stent inser-
tion may reduce the risk of urological complications such as ureteral strictures and leak-
ages.4,9,10 However, concerns have been raised regarding potential stent-related compli-
cations, such as urinary tract infections (UTI), stent breakage or migration, reflux, stone 
formation, hematuria, and secondary ureter obstruction.4,11,12 Some centers, including 
ours, have a prophylactic stenting policy; however, in most centers, surgeons base their 
choice on earlier experiences, training, and personal preferences. The Cochrane review 
from Wilson and associates debates which stent caliber and stent duration is best to 
avoid urological complications. Although the type of stent was mostly similar (double J 
stent was used in all but 1 study), the time until stent removal diverged from 7 days until 
3 months and stent caliber varied from 5F to 7F between all studies.4 To our knowledge, 
no studies have been published that compared the influence of different externalized 
ureteric stents on the number of urological complications in kidney transplant recipients.
In our center, we prefer the use of external stents over double J stents because of several 
advantages, such as the possibility of monitoring urine production and the simplicity of 
stent removal without a cystoscopy. Furthermore, we have no double J-related compli-
cations such as “the forgotten stent” or stent encrustation.13,14 We have used 2 different 
types of external ureteral stents as standard care in the past years. As guidelines in 
literature are not equivocal, we conducted a database analysis to evaluate the outcomes 
of these 2 kinds of stents used during kidney transplant.
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Methods 
We included all patients who received a kidney transplant with an externalized stent from 
January 2013 to January 2015. We considered bilateral kidney transplants and pediatric 
kidney transplants as exclusion criteria. From January 2013 until January 2014, patients 
were treated with type A stents, and the following year until January 2015 patients were 
treated with type B stents. Type A stents refers to a 8F “Covidien” polyvinyl chloride tubes 
(Covidien, Dublin, Ireland) and type B stents refers to a 7F polyurethane “Teleflex” single J 
stent (Teleflex Medical, Athlone, Ireland) (Figures 1 and 2). Kidney donors were either de-
ceased or living. Recipient characteristics, clinical information, and follow-up data were 
retrospectively obtained from electronic patient records. Data regarding graft function 
were limited to 6 months after transplant. Data regarding rejection episodes, PCN place-
ment, and patient and graft survival were reviewed during complete follow-up (until 
July 2015). Graft failure was defined as patient’s return to hemo- or peritoneal dialysis, if 
graft nephrectomy was performed, or if the patients received a new preemptive kidney 
transplant. This study received approval from our center’s medical ethics committee.
Definitions
A UTI was defined as an infection of the urinary tract with a positive bacterial culture of the 
urine sample for which treatment with antibiotic therapy was given. Only UTIs within the 
first 3 months after surgery were considered. A urological complication was defined as 
urinary leakage or ureteral stricture requiring PCN placement; PCN placement is considered 
to be the first step in the treatment of urological complications. Percutaneous nephros-
tomy placement was indicated when postoperative ultrasonography revealed hydro-
nephrosis in combination with a rising serum creatinine level or a perirenal urinoma 
indicating urine leakage, confirmed by ultrasonography or renal MAG-3 (radioisotope 
renography) scanning. Stents removed before day 8 were registered as dysfunctional.
Surgical procedure
If a kidney graft had multiple renal arteries, an arterial reconstruction was made. In the 
recipient, the renal vein was anastomosed to the external iliac vein and the renal artery 
to the external iliac artery. All patients underwent an extravesical Lich-Gregoir anasto-
mosis of the ureter with the introduction of a suprapubic externalized stent. The stent 
was removed manually on postoperative day 9. A transurethral catheter in the bladder 
was left in situ until postoperative day 7. A wound drain was placed and removed after 1 
or 2 days, depending on the amount of drain production.
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Immunosuppressive regimen
Almost all patients received a similar immunosuppressive regimen. This included induc-
tion therapy with basiliximab (Simulect®, Novartis Pharmaceuticals, Basel, Switzerland) 
and maintenance therapy with tacrolimus (Prograft®, Astellas Pharma, Tokyo, Japan), 
mycophenolate mofetil (Cellcept®, Roche, Basel, Switzerland), and glucocorticoids. 
On indication, a conversion of aforementioned immunosuppressive medications was 
performed in individual patients, such as additional antithymocyte globulin induction 
therapy or belatacept (Nulojix®, Bristol Myers-Squibb, New York City, NY, USA) instead of 
tacrolimus.
Figure 1. Type A 8F Stent (Left) and Type B Single J 7F Stent (Right)
Figure 2. Type A 8F Stent (Left) and Type B Single J 7F Stent (Right)
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Statistical analyses 
All statistical analyses were performed with SPSS software (SPSS: An IBM Company, ver-
sion 21.0, IBM Corporation, Armonk, NY, USA). Categorical variables are presented as 
numbers with percentages and analyzed using chi-squared test. Continuous variables 
with normal distribution are presented as means with standard deviation and analyzed 
using the independent t test. Skewed distributed variables are presented as median 
(range) and analyzed using the Mann-Whitney U test. Graft survival was analyzed us-
ing the Kaplan-Meier method, and a log-rank test was conducted to compare survival 
curves. Two-tailed P values of < 0.05 were considered statistically significant.
Results 
Baseline characteristics
Between January 2013 and January 2015, 370 patients received kidney transplants with 
external stenting at our hospital. Four patients were excluded from our study: 3 patients 
because of bilateral kidney transplant and 1 because of a pediatric kidney graft. Our co-
hort consisted of 197/366 patients (54%) receiving type A stenting and 169/366 patients 
(46%) receiving type B stenting. Our patient group comprised 230 male patients and 136 
female patients. The mean age of recipients was 55 ± 15 years. Demographic details of 
kidney recipients, kidney grafts, and transplants are presented in Table 1. There were no 
significant differences between both groups, except for the length of follow-up.
Urological complications 
In our patient group, 50/366 patients (14%) required PCN placement, in which 37 pa-
tients (10%) underwent a PCN placement due to hydronephrosis and 13 patients (4%) 
due to urinary leakage (Table 2).
The incidence of PCN placement was significantly higher with type A stenting (17% vs 
9%; P = 0.030). Median time between transplant and PCN placement was 17 days (range, 
2-190 d) and did not differ significantly between groups; reason for PCN placement also 
did not differ. Urinary tract infections within the first 3 months after transplant occurred 
more often in patients who received type B stenting (37% vs 26%; P = 0.034). Three 
patients with type A stenting and 2 patients with type B stenting underwent balloon 
dilatation of the strictured segment of the ureter. Open ureter revision was performed 
in 7 patients with PCN in type A stenting, with 5 due to hydronephrosis and 2 due to 
persistent urine leakage. Only 1 patient who had type B stenting underwent surgical 
ureter revision. This patient was clinically suspected to have an anastomotic leak and 
was not treated with PCN but underwent immediate ureter revision.
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In Table 3, the baseline characteristics of the patients who received a PCN are docu-
mented. As shown, there were significantly more patients who were transplanted in the 
left fossa and more patients who received a retransplant in the patient group with type 
A stent who received a PCN.
Stent-related complications
Ureteric stents were removed after a median of 9 days (range, 1-12 d) in patients with 
type A and type B stents (Table 2). Stents were equally often removed prematurely (< 8 
d) in both groups (17% vs 13%; P = 0.261). No significant differences were found between 
the 2 groups regarding reason for early stent removal (hydronephrosis, obstruction, 
migration, spontaneously, early graft nephrectomy or other) (P = 0.397).
Table 1. Baseline Characteristics 
 
Total 
Group
(n = 366)
Ureteric
 Type A Stent
(n = 197)
Ureteric 
Type B Stent
(n = 169)
P-value
Recipient age (y), mean ± SD 55 ± 15 55 ± 14 56 ± 15 0.378
Recipient sex
Male N (%) 230 (63) 119 (60) 111 (66) 0.298
Female N (%) 136 (37) 78 (40) 58 (34)
Type of donor
Deceased N (%) 128 (35) 66 (33.5) 62 (37) 0.524
Living N (%) 238 (65) 131 (66.5) 107 (63)
Multiple transplants N (%) 69 (19) 43 (22) 26 (15) 0.116
Preemptive transplant N (%) 132 (36) 76 (39) 56 (33) 0.280
Body mass index (kg/m2), mean ± SD 27 ± 5 26 ± 5 27 ± 5 0.848
Multiple arteries N (%) 94 (26) 46 (23) 48 (28) 0.270
Implantation side 
Left N (%) 74 (20) 41 (21) 33 (20) 0.760
Right N (%) 292 (80) 156 (79) 136 (80)
Operating time (min), mean ± SD 141 ± 40 140 ± 39 143 ± 41 0.546
Warm ischemic time (min), median (range) 20 (10-149) 20 (10-149) 20 (11-43) 0.839
Cold ischemic time (min), median (range) 164 (95-1440) 162 (95-1410) 170.5 (100-1440) 0.569
Blood loss during surgery (mL), median (range) 200 (0-18 000) 200 (0-3600) 200 (0-18 000) 0.274
Hospital admission (d), median (range) 14 (9-142) 14 (9-123) 14 (9-142) 0.332
Stent duration (d), median (range) 9 (1-12) 9 (1-12) 9 (1-12) 0.227
Follow- up duration (mo), median (range) 14 (0-34) 20 (0-34) 10 (0-17) <0.001
SD, standard deviation; Y, years; Min, minutes; d, days; mo, months
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Overall complications
Graft rejection occurred significantly more often in patients who received the type B stent 
than in patients who received the type A stent (37% vs. 22%; P = 0.002) (Table 2). Surgical 
reinterventions regarding the transplant were performed in 33 patients (including the 
previously mentioned 8 patients who underwent ureter revision) and occurred equally 
often in both groups (6% vs 3%; P = 0.055). Reasons for surgical reinterventions in the 
type A stenting group were graft nephrectomy, postoperative bleeding, venous throm-
bectomy, abdominal wall abscess, and retransplant. Reasons for surgical reinterventions 
in the type B stenting group were graft nephrectomy, postoperative bleeding, suspected 
necrotizing fasciitis, fascial dehiscence, abdominal wall hematoma, and incisional hernia. 
The incidence of surgical procedures not related to transplant, performed in the first year 
after transplant, was not significantly different for both groups (11% vs 6%; P = 0.116).
Table 2. Urinary, Overall, and Stent-Related Complications
 
Total Group
(n = 366)
Ureteric Type A 
Stent (n = 197)
Ureteric Type B 
Stent (n = 169)
P-value
Urinary complications
PCN placement N (%) 50 (14) 34 (17) 16 (9) 0.030
Time to PCN placement (d), median (range) 17 (2-190) 15.5 (4-159) 33 (2-190) 0.588
Reason for PCN placement
Urinary leakage N (%) 13 (4) 10 (5) 3 (2) 0.089
Hydronephrosis N (%) 37 (10) 24 (12) 13 (8) 0.155
Radiological balloon dilatation N (%) 5 (1) 3 (2) 2 (1) 0.780
Ureter reconstruction/reimplant N (%) 8 (2) 7 (4) 1 (1) 0.053
Urinary tract infection N (%) 114 (31) 52 (26) 62 (37) 0.034
Stent-related complications
Early stent removal N (%) 56 (15) 34 (17) 22 (13) 0.261
Reason for early stent removal (< 8 d)
Spontaneously N (%) 15 (4) 9 (5) 6 (4)
Hydronephrosis N (%) 4 (1) 2 (1) 2 (1)
Obstruction N (%) 18 (5) 13 (7) 5 (3)
Migration N (%) 4 (1) 2 (1) 2 (1)
Early transplantectomy N (%) 3 (1) 3 (2) 0 (0)
Other N (%) 12 (3) 5 (3) 7 (4)
Overall complications
Wound infection ≤ 3 mo N (%) 21 (6) 12 (6) 9 (5) 0.753
Surgical reinterventions regarding transplant N (%) 33 (9) 23 (6) 10 (3) 0.055
Other surgical procedures ≤ 12 mo N (%) 62 (17) 39 (11) 23 (6) 0.116
Rejection therapy N (%) 105 (29) 43 (22) 62 (37) 0.002
Time to rejection therapy (mo), median (range) 0 (0-16) 0 (0-16) 0 (0-10) 0.490
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Graft function and survival
Glomerular filtration rate and serum creatinine levels were not significantly different 
between the groups, except for month 6, which showed higher serum creatinine levels 
in the type B stenting group (median 135 vs 126 μmol/L; P = 0.030) (Table 4). As shown 
by the Kaplan-Meier curve, kidney graft survival did not differ significantly between the 
groups (P = 0.781) (Figure 3). The 3-month, 6-month, and 1-year graft survival rates in 
the type A stenting group were 97%, 96%, and 95%, with corresponding rates in the 
type B stenting group of 98%, 97%, and 95% (P = 0.781). The 3-month, 6-month, and 
1-year patient survival rates in the type A stenting group were 99%, 98%, and 98%, with 
corresponding rates in the type B stenting group of 99%, 98%, and 95% (P = 0.093).
Table 3. Baseline Characteristics of Patients With Percutaneous Nephrostomy
 
Total Group
(n = 50)
Ureteric Type A 
Stent (n = 34)
Ureteric Type B 
Stent (n = 16)
P-value
Recipient age, mean ± SD 55 ± 15 55.5 ± 14 57 ± 16 0.700
Recipient sex
Male N (%) 30 (60) 20 (59) 10 (63) 0.804
Female N (%) 20 (40) 14 (41) 6 (37)
Type of donor
Deceased N (%) 17 (34) 9 (27) 8 (50) 0.101
Living N (%) 33 (66) 25 (73) 8 (50)
Multiple transplants N (%) 7 (14) 7 (21) 0 (0) 0.050
Preemptive transplant N (%) 14 (28) 10 (29) 4 (25) 0.746
Body mass index (kg/m2), mean ± SD 27 ± 5 27 ± 5 27 ± 4 0.961
Multiple arteries N (%) 11 (22) 10 (29) 1 (6) 0.065
Implant side 
Left N (%) 8 (16) 8 (23) 0 (0) 0.034
Right N (%) 42 (84) 26 (77) 16 (100)
Operating time (min), mean ± SD 138 ± 35 136 ± 31 142 ± 42 0.606
Warm ischemic time (min), median (range) 19 (13-43) 19 (13-32) 19 (13-43) 0.676
Cold ischemic time (min), median (range) 159 (104-1440) 153 (110-1263) 215.5 (104-1440) 0.149
Blood loss during surgery (mL), median (range) 250 (0-3100) 200 (0-1600) 325 (0-3100) 0.500
Hospital admission (d), median (range) 16 (10-123) 17 (11-123) 15.5 (10-29) 0.453
Stent duration (d), median (range) 9 (1-10) 8 (1-9) 9 (6-10) 0.191
Follow- up duration (mo), median (range) 16.5 (2-27) 19.5 (3-27) 9 (0-15) <0.001
SD, standard deviation; Y, years; Min, minutes; d, days; mo, months
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Discussion 
The aim of this retrospective study was to evaluate the influence of 2 different types of 
externalized ureteric stents (type A was an 8F polyvinyl chloride tube and type B was a 
7F polyurethane single J stent) on the incidence of urological complications. We found 
a significantly higher incidence of PCN placements in patients who received the type 
A stent and a higher incidence of rejection and UTI in patients who received the type 
B stent. There were no significant differences in the reason for PCN placement or for 
patient or graft survival between both groups.
An explanation for the higher number of PCN placements in the type A stent group 
may be that this stent has fewer drainage holes and may therefore obstruct relatively 
easier. Obstructed stents can potentially cause a hydronephrosis of the kidney graft, ne-
cessitating PCN placement. However, as the median time between transplant and PCN 
placement was 17 days, stents were mostly already removed at the time of PCN place-
ment. Furthermore, we found no differences between the groups regarding early stent 
removal due to stent obstruction. Another likely explanation for the higher number of 
PCN placements with type A stents could be its wider 8F caliber. This could potentially 
cause edema of the ureter after stent removal, which could explain several temporally 
Table 4. Graft Function
Total Group
(n = 366)
Ureteric Type A 
Stent (n = 197)
Ureteric Type B 
Stent (n = 169)
P-value
GFR after transplant (ml/min), mean ± SD
Day 1 20 ± 14 20 ± 14 20 ± 14 0.963
Day 2 30 ± 21 30 ± 21 30 ± 22 0.721
Day 3 32 ± 22 32 ± 22 33 ± 22 0.914
Day 7 35 ± 21 35 ± 20 36 ± 22 0.421
Month 1 46 ± 16 47 ± 16 45 ± 17 0.352
Month 3 47 ± 15 47 ± 15 46 ± 16 0.330
Month 6 48 ± 16 49 ± 16 46 ± 16 0.079
Serum creatinine after transplant(μmol/L) median (range)
Day 1 319.5 (67-1810) 307 (67-1810) 334 (81-1745) 0.858
Day 2 205 (54-1619) 203 (54-1619) 219 (68-1462) 0.712
Day 3 186 (51-1765) 183.5 (51-1765) 188 (64-1327) 0.888
Day 7 166 (50-1213) 166.5 (58-1091) 163 (50-1213) 0.728
Month 1 132 (59-652) 129 (64-652) 135 (59-562) 0.125
Month 3 132 (64-419) 131 (64-419) 134 (64-272) 0.102
Month 6 130 (47-301) 126 (47-293) 135 (61-301) 0.030
GFR, glomerular filtration rate; SD, standard deviation
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PCN placements due to passing hydronephrosis without demanding an additional in-
vention such as surgical reconstruction or balloon dilatation. It is possible that this larger 
caliber stent also caused transient ischemia of the ureter due to higher pressure on the 
ureteral wall, resulting in more ureteral stenosis requiring reinterventions. Although the 
number of surgical and balloon reinterventions was not signifi cantly higher in type A 
stenting (P = 0.053), a trend can be detected in favor of type B stenting.
Urinary tract infections are common complications after kidney transplant with a re-
ported incidence of 26% to 98%.15-17 Although lower UTIs are often thought to be of a 
mild nature, some studies suggest that UTIs can contribute to the development of acute 
allograft rejection and possibly even compromise graft function in the short term.18,19 
The incidence of UTIs within the fi rst 3 months after transplant in our study was higher 
in the type B stent group. This could not be explained by the type of stent material, as a 
study of Lopez and associates found that polyurethane catheters (stent type B) had lower 
Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, and Pseudomonas 
aeruginosa adherence compared with polyvinyl chloride catheters (our type A stent).20 
Figure 3. Kaplan-Meier Graft Survival Curve
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Another explanation for the higher number of UTIs could be the higher rejection rate 
shown in the group B stent patients. Acute rejection episodes are treated with high-dose 
immunosuppressive therapy, leading to increased risk of infections.21 Incidences of graft 
rejection might be increased during the past few years because of shifting boundaries 
for donor acceptance and because increasingly more ABO-incompatible transplants are 
being performed in our center.22 A causal association between stent material and rejec-
tion episodes seems highly unlikely.
One important limitation of this study was its retrospective design. Another drawback 
was the limited follow-up period, especially in patients who received the type B stent. 
However, the protective effects of the stent are expected to be the most significant dur-
ing the first weeks after transplant.
To our knowledge, no other study has compared 2 different types of externalized 
ureteral stents used in kidney transplant. There are some studies available that have 
compared double J versus external ureteral stents. Vogel and associates retrospectively 
compared these 2 stents and concluded that the external stent had significantly more 
urinary leakage (14% vs 0%) and more hospitalization days for patients without im-
munological complications (13 vs 11 days).23 Gomes and associates also found more 
urological complications with external stenting compared with double J stenting (17% 
vs 5%); however, this was also a retrospective study.24 Another way of stenting the 
ureteroneocystostomy is by using an internal stent tied to a Foley catheter. This way, 
the stent is removed simultaneous during Foley catheter removal. This technique was 
described by Taghizadeh-Afshari and associates in 2014. They randomized 90 patients 
into 2 study groups, with 1 group having the stent attached to the Foley catheter and 
the group having these separated. They reported a urinary leakage rate of 3.3%, with all 
of these occurring in the separated stent group. Furthermore, they report 0% stent crus-
tation in the attached group. However, a drawback of their study was the small sample 
size.25 More prospective research is necessary to compare other ureteral stents types 
and to clarify which type of stent establishes the least number of urological complica-
tions and best renal outcome.
In conclusion, we found a significantly higher PCN placement rate in patients who re-
ceived the type A stent versus that shown in patients who received the type B stent. The 
type B stent was associated with more UTIs and higher rejection rate compared with the 
type A stent, without influencing patient and graft survival.
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Abstract
The aim of this study is to evaluate the role of ureteral length on urological complica-
tions. Data were retrospective collected from the INEX-trial database, a RCT to compare 
the intravesical to the extravesical ureteroneocystostomy. Ureteral length was measured 
in 198 recipients and used to divide recipients into 3 categories based on interquartile 
ranges: Short (≤8.5cm), medium (8.6-10.9cm) and long ureters (≥11cm). Urological com-
plications were defined as the number of percutaneous nephrostomy placements (PCN). 
Fifty recipients fell into the short, 98 into the medium and 50 recipients into the long 
ureter category. Median follow-up was 26 (range 2-45) months. There was no significant 
difference in number of PCN placements between the categories. There were 9 (18%) 
PCN placement in the short ureter category, 21 (20%) in medium ureter category and 
10 (21%) PCN placements in the long ureter category, p=0.886. Risk factor analysis for 
gender, arterial multiplicity and type of ureteroneocystostomy showed no differences 
in PCN placements between the three ureteral length categories. We conclude that ure-
teral length alone does not seem to influence the number of urological complications.
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Introduction
Reducing ureter-related complications remains one of the challenges in kidney trans-
plantation. Major urological complications, such as urinary leakage and ureter strictures, 
may lead to increased morbidity and prolonged hospital stay (1, 2) and are reported with 
an incidence of overall urological complications has been reported between 4.8-20% (3, 
4). Multiple factors are presumed to contribute to the development of urological com-
plications. The infl uence of donor and recipient factors are being discussed in literature 
and include: male gender of recipient and donor, arterial multiplicity and pre-emptive 
transplantation as possible risk factors for urological complication (5).
Some other factors that may contrib-
ute to the development of urological 
complications after kidney trans-
plantation are graft related, such as 
ureteral vascularization and arterial 
multiplicity (6). Diminished blood sup-
ply of the ureter can cause ischemia 
of the most distal part of the ureter, 
resulting in urinary leakage or ureter 
strictures. The native vascularization 
of the ureter is by segmental arteries 
derived from the renal, vesicle, go-
nadal, common iliac or internal iliac 
vessels or directly from the abdominal 
aorta (Figure 1). During living donor 
nephrectomy most of these segmen-
tal branches are dissected, resulting 
in the renal artery as the main blood 
supply of the ureter. Therefore, it is 
assumed that a shorter ureteral length 
is accommodated with better vascu-
larization and may possibly cause less 
urological complications.
Because of the limited knowledge about the infl uence of ureteral length on urological 
complications after kidney transplantation, we have conducted this study using the 
available data of the recently published randomized controlled INEX-trail (7).
Figure 1. Vascularization of ureter
A. Renalis
A. Gonadalis
Aorta
A. Iliaca Communis
A. Iliaca Interna
A. Vesicalis Superior
A. Uterina
A. Rectalis Media
A. Vesicalis Inferior
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Methods
Study population and data selection
Between October 2010 and December 2012 a randomized controlled trial, referred 
to as the INEX-study, was conducted in our center (7). In this study, 200 consecutive 
recipients of a living donor kidney transplant were randomized to either an intravesical 
or extravesical ureteroneocystostomy. Exclusion criteria were age <18years, a double 
ureter system of the donor kidney, robot-assisted donor nephrectomy using the DaVinci 
Surgical System or an absent native bladder of the recipient. During this trial ureteral 
length was measured and documented prospectively in all kidney transplant recipients.
Baseline characteristics included; recipient gender, age, body mass index (BMI), warm 
and cold ischemia time, duration of operation, number of donor renal arteries and 
median follow-up in months. Total ureteral length was measured intra-operatively from 
the center of the pyelum to the most distal part of the ureter. After the vascular anas-
tomoses had been performed, the ureter was prepared for the ureteroneocystostomy. 
The kidney was placed in its preferred position before cutting the excess length of the 
ureter. The length of a ureter is ideal when a tension free anastomosis can be made 
and the risk of ureteral rotation or kinking is minimalized. The length of the removed 
segment was measured and then subtracted from the total ureteral length, representing 
the remaining ureteral length in the recipient for this study. Recipients were divided into 
3 categories based on the interquartile ranges of ureteral length. Patients with a ureteral 
length at or below the 25th percentile were placed in the lowest category (short ureter 
category), the ureteral lengths above the 75th percentile in the highest category (long 
ureter category) and the middle 50 percent in the moderate category (medium ureter 
category).
Percutaneous nephrostomy (PCN) placement during complete follow-up was used as a 
primary outcome for urological complications, since PCN placement is considered to be 
the initial treatment for major urological complications, like urinary leakage or ureteral 
stenosis. The reason for PCN placement and the consecutive treatment were document-
ed. Urinary leakage, (detected by a MAG-3 scan or proven by chemistry samples in case 
of extensive fluid production of the wound or by the drain) or a rise in serum creatinine 
level combined a hydronephrosis on ultrasound, indicated PCN placement.
Risk factor analysis
A risk factor analysis was performed to determine the relationship between the numbers 
of PCN placements in the three ureteral length categories by analysing each potential 
risk factor separately. Based on available literature, we selected: recipient gender, arte-
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rial multiplicity of the kidney graft and type of ureteroneocystostomy as potential risk 
factors (5, 8).
Surgical technique in the recipient
The extraperitoneal approach in the iliac fossa was performed in all recipients. All kidney 
grafts with multiple arteries had an arterial reconstruction prior to transplantation. This 
was either side to end or side to side on the main renal artery. After the (end-to-side) 
vascular anastomoses on the external iliac vessels, a consultant transplant surgeon 
performed either an intravesical anastomosis described by Politano-Leadbetter (9) or 
an extravesical anastomosis described by Lich-Gregoir (10, 11) as determined by ran-
domization to create continuity of the urinary tract. A ureterovesical 8- French stent was 
used as part of our standard care and was externalized suprapubically. The stent was 
removed 9 days postoperatively. An urinary bladder catheter was placed and removed 
after 7 days.
Immunosuppressive treatment
Immunosuppressive treatment consisted of basiliximab intravenous on the day of sur-
gery and day 4 after transplantation. Postoperative immunosuppression consisted of 
tacrolimus, mycophenolate mofetil and prednisolone. The prednisolone was tapered off 
to be discontinued at 4 months after transplantation.
Statistical analysis
Categorical variables were presented as numbers (percentage). Continuous variables 
were presented as means with standard deviation if normally distributed or as median 
with range if not normally distributed. Continuous variables were analysed using the 
one-way ANOVA or Kruskal-Wallis test. Categorical variables were analysed using Chi-
square test. Risk factor analysis was performed using logistic regression with PCN as 
outcome and the interaction of ureteral length categories and gender, type of uretero-
neocystostomy and arterial multiplicity as predictors. All analyses were conducted using 
IBM SPSS Statistics for Windows (version 21.0. Armonk, NY: IBM Corp, USA). A p-value of 
<0.05 (two-sided) will be considered statistically significant.
Results
Baseline characteristics
Between October 2010 and December 2012, a total of 200 recipients were included in 
the INEX trial (7). Ureteral length was measured in 198 recipients. Mean ureteral length 
of all recipients was 9.6cm ± 1.6cm. Recipients were divided into three different catego-
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ries. Fifty recipients were allocated to the short ureter category (≤8.5cm), with a mean 
ureteral length of 7.5cm ±0.9cm. Nighty-eight recipients were allocated to the medium 
ureter category (8.6cm-10.9cm), mean ureteral length was 9.7cm ±0.6cm and 50 re-
cipients were allocated to the long ureter category (≥11cm), mean ureteral length was 
11.7cm ±0.6cm. All ureters were shortened during surgery; the removed segment size 
had a mean of 4.7cm ± 2.1cm. Table 1 provides an overview of baseline characteristics 
of the three categories. No significant differences were found between recipient gender 
and age, BMI, ischemia time, duration of operation or follow-up in months. The median 
follow-up of all recipients was 26 (2-45) months.
Urological outcome
There was no significant difference in the number of PCN placements between the three 
categories (Table 2 and Figure 2).
In the short ureter category (≤8.5cm), 9 recipients (18%) were treated with a PCN. Eight 
recipients received a PCN due to hydronephrosis, and 1 recipient had urinary leakage. 
Median time between transplantation and PCN placement was 9 days (range 3-182 
days). The recipient with urinary leakage recovered from the leakage without any 
other intervention. However, this recipient developed a ureter stricture one year after 
transplantation for which a ureter reconstruction was performed. Of the 8 recipients 
with a PCN placement due to hydronephrosis, one had immediately surgical ureter 
reconstruction and another recipient underwent an unsuccessful percutaneous balloon 
dilatation of a ureter stricture followed by surgical ureter reconstruction. In 6 recipients, 
the hydronephrosis resolved without any other intervention (Table 2 and Figure 2).
Table 1. Baseline characteristics
Variable Short ureter 
(n=50)
Medium 
ureter (n=98)
Long ureter
(n=50)
P-value
Recipient age in years mean ± SD 52 ± 14 55 ± 13 55 ± 14 0.514 
Recipients gender
- Male N (%) 29 (58) 66 (67) 34 (68) 0.469  
- Female N (%) 21 (42) 32 (33) 16 (32)  
Recipients BMI mean ± SD 26 ± 5 26 ± 5 27 ± 4 0.583 
Warm ischemia in minutes mean ± SD 26 ± 7 26 ± 6 27 ± 14 0.498 
Cold ischemia in minutes mean ± SD 147 ± 25 150 ± 29 149 ± 32 0.773 
Duration operation in minutes mean ± SD 131 ± 25 133 ± 29 135 ± 31 0.808 
Follow-up in months median (range) 29 (3-44) 25.5 (2-45) 25 (11-44) 0.235
Ureteral length in cm mean ± SD 7.5 ± 0.9 9.7 ± 0.6 11.7 ± 0.6 <0.001 
SD, standard deviation; M, Male; F, Female; BMI; body mass index
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In the medium ureter category (8.6-10.9cm), 21 recipients (21%) had a PCN placement. 
In 17 recipients (81%) it was because of hydronephrosis and in 4 recipients (19%) due to 
urinary leakage. Median time between transplantation and PCN placement was 12 days 
(range 2-86 days). All 4 recipients with urinary leakage recovered without any other in-
tervention. Of the 17 recipients with PCN placement due to hydronephrosis, 4 recipients 
underwent surgical re-intervention because of a ureter stricture, 2 underwent successful 
percutaneous balloon dilatation and in 10 recipients, the hydronephrosis resolved with-
out any other intervention. In 1 recipient, the hydronephrosis was due to obstruction 
due to nephrolithiasis in the kidney graft 9 months after transplantation. This recipient 
underwent percutaneous nephrolithotomy and the PCN could be removed successfully 
afterwards (Table 2 and figure 2).
In the long ureter category (≥11cm) 10 recipients (20%) were treated with a PCN. Eight 
recipients had hydronephrosis (80%) and 2 recipients (20%) urinary leakage. Median 
time between transplantation and PCN placement was 7 days (range 3-29 days). There 
was no need for any re-intervention for the recipients with urinary leakage. In 8 recipi-
ents with a hydronephrosis, one recipient with a ureter stricture underwent successful 
percutaneous balloon dilatation. In the other 7 recipients, hydronephrosis resolved 
without additional intervention (Table 2 and Figure 2).
Risk factor analysis
In total 31/129 (24%) males and 9/69 (13%) females received PCN placement. Thirty-
six out of 198 patients had arterial multiplicity of the kidney graft of whom 9/36 (25%) 
received a PCN. This group contained 19/36 kidneys with a lower pole artery, of whom 
6/19 (32%) received a PCN and 17/36 kidneys with an additional (non-lower pole) artery, 
Table 2. Urological complications
Variable Short ureter 
(n=50)
Medium ureter 
(n=98)
Long ureter
(n=50)
P-value
PCN N (%) 9 (18) 21 (21) 10 (20) 0.886 
Days between KT-PCN median (range) 9 (3-182) 12 (2-86) 7 (3-29) 0.367 
Reason PCN N=9 N=21 N=10
- Hydronephrosis N (%) 8 (89) 17 (81) 8 (80) 0.847  
- Urinary leakage N (%) 1 (11) 4 (19) 2 (20)  
Treatment PCN N=9 N=21 N=10
- No N (%) 6 (67) 14 (67) 9 (90) 0.493 
- Balloon dilatation N (%) 1 (failed) 2 (9) 1 (10)  
- Ureteral revision N (%) 3 (33) 4 (19) -  
- Nephrolithotomy N (%) - 1 (5) -  
KT, Kidney transplantation; PCN, percutaneous nephrostomy
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of whom 3/17 (18%) received a PCN. Furthermore, in 20/100 (20%) patients with an 
extravesical ureteroneocystostomy a PCN was placed and 20/98 (20%) patients with an 
intravesical anastomosis. Risk factor analysis was performed using logistic regression 
with PCN as outcome and the interaction of ureteral length categories and gender, 
type of ureteroneocystostomy and arterial multiplicity as predictors. The interaction 
between gender and ureteral length category was not significant (p=0.355), neither 
was the interaction for arterial multiplicity (p=0.152), nor the interaction for the type of 
ureteroneocystostomy (intra- vs extravesical)(p=0.239). Therefore, we cannot conclude 
differential effects of the risk factors in the three categories.
Discussion
Based on the available anatomical knowledge of the ureteral vascularization, it is 
presumed that a shorter ureteral length is preferable to a longer ureter in kidney trans-
plantation. However, in this study, we found that ureteral length alone does not seem to 
contribute to the number of urological complications. We performed a risk factor analy-
sis for recipient gender, arterial multiplicity and for type of ureteroneocystostomy. There 
were no differential effects of these risk factors in the three ureteral length categories.
In a study by Ali-Asgari et al. the complication rate, long term survival and hospitalization 
days were not significantly different between ureters less or more than 5,5cm. However, 
no information could be found on the technique of ureteral length measurement (12).
Slagt et al. previously analyzed risk factors for urological complications in deceased 
donor kidney transplantation. Multivariate analysis showed that male recipients and 
arterial reconstructions were independent risk factors for urological complications (5). 
Carter et al. also stated that arterial multiplicity increases the risk of urological complica-
tions after living kidney transplantation, confirming the earlier findings by Kok et al. (6, 
8). Unfortunately, analysis of the influence of a lower pole artery could not be performed 
adequately due to the limited number of patients with a lower pole artery in this series.
There are some limitations to this study. The measurements of the ureteral length were 
part of the earlier published INEX-trial. In this randomized controlled trial, the intravesi-
cal vs. extravesical ureteroneocystostomy were compared. Therefore, our study popula-
tion is not uniform. However, in the INEX-trial the number of urological complications 
were the same in both groups (7). Furthermore, different transplant surgeons measured 
the ureteral length and inter-observer bias of a few millimeters could not be excluded.
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Our number of urological complications, defined by PCN placements, is high compared 
to literature. We have a relatively large number of patients who received a PCN due to 
hydronephrosis, which resolved without any treatment 23/40 (58%). This is probably 
because in our center PCN placement is considered to be a minimal invasive interven-
tion and we therefore maintain a low threshold to place a PCN. A bit hydronephrosis 
leads to PCN placement either for therapeutic benefit but also as a diagnostic tool. If we 
would exclude these PCN placements due to hydronephrosis which needed no addi-
tional intervention, the short ureter category would include 3/50 (6%) PCN placements, 
the medium ureter 11/98 (11%) and the long ureter 3/50 (6%), p=0.423. Therefore, still 
ureteral length does not seem to influence the number of PCN placements.
If neither the ureteral length, nor the technique for ureteroneocystostomy are factors 
that contribute to urological complications, the use of a ureteral stent may be ques-
tioned. In our institute, a ureterovesical stent is placed routinely. The Cochrane review 
of Wilson et al. report a urological complication rate of 0-4% in the stented group vs. 
0-17.3% in the non-stented group. However, the number of urinary tract infections is 
significantly higher in the stented group and stent-related complications, like obstruc-
tion, migration and stone formation, should not be neglected. We agree with the authors 
of the Cochrane review that a well-designed study of stenting versus selective stenting 
should be executed (13).
Additionally, more insight should be established in the microcirculation and perfusion 
of the ureteral blood flow. To our knowledge, only 1 animal study has been published 
about the effect of ureteral access sheath on microcirculation of the ureter. Lallas et 
al. demonstrated that the use of the access sheath can cause a transient decrease in 
ureteral blood flow (14). This raises the question whether the use of a ureterovesical 
stent in kidney transplantation also influences the microcirculation of the ureter.
We conclude that ureteral length alone does not seem to influence the number of uro-
logical complications after kidney transplantation. Risk factor analysis for recipient gen-
der, arterial multiplicity and for type of ureteroneocystostomy provided no differential 
effects between the three categories. Further research on the microvascular blood flow 
of the ureter and the use of a ureterovesical stent is warranted to answer more questions 
about risk factors for urological complications in living donor kidney transplantation.
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Abstract
The aim of this study was to investigate the effect of antegrade balloon dilatation on 
ureteral strictures that developed after kidney transplantation (KT). Hospital database 
of the Erasmus Medical Center (EMC), Rotterdam, and the Academic Medical Center 
(AMC), Amsterdam, were retrospectively screened for patients that underwent balloon 
dilatation after KT. Balloon dilatation was technically successful whenever it was able 
to pass the strictured segment with the guidewire followed by balloon inflation, and it 
was clinically successful if no further interventions, for instance surgical revision of the 
ureteroneocystostomy or prolonged double J placement, were necessary. Fifty patients 
(2.4%) out of 2075 kidney transplantations underwent antegrade balloon dilatation 
because of urinary outflow obstruction. Median time between KT and balloon dilata-
tion was 3 (0-139) months. In 43/50 (86%) patients balloon dilatation was technically 
successful and in 7 (14%) patients it was impossible to pass the strictured segment with 
the guidewire. In 20/43(47%) technically successful patients, the procedure was also 
clinically successful, with median follow up after balloon dilatation of 35.5 months (0-
102). We did not identify patient or stricture characteristics that influenced the outcome 
of treatment. Balloon dilatation is a good option for ureter stricture treatment after KT 
as its minimal invasive and can prevent surgical exploration in almost half of the cases.
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Introduction
Major urological complications after kidney transplantation (KT), including urinary 
leakage and ureter strictures, are reported with an incidence between 2.3-20% 1-3. Ure-
teral strictures are the most commonly reported urological complication and can cause 
significant morbidity after KT with prolonged hospital stay and repetitive interventions.
A ureteral outflow obstruction is characterized by elevated serum creatinine in combi-
nation with hydronephrosis on ultrasound examination and is generally treated with a 
percutaneous nephrostomy (PCN). In several cases the obstruction will resolve spon-
taneously, but in a few cases additional treatment is necessary to guarantee adequate 
outflow.
Treatment options for ureteral strictures include long term double J catheter insertion, 
balloon dilatation or surgical revision of the ureteroneocystostomy. In the literature, only 
a few studies are available that report on the success-rate of these treatments. Helfand 
et al. report on their experience with surgical management of ureteral strictures after KT 
and proposed an algorithm for the management of strictures 4. The algorithm is based 
on size of the stricture (<3cm) and the time between transplantation and diagnosis of 
the stricture (<3 months). However, the study population was small (n=13) 4.
Balloon dilatation has proven its efficacy in the treatment of the ureterovesical junction 
for an obstructive mega-ureter and in uretero-ileal strictures of 1cm or less in patients 
after surgical urinary diversion 5-7.
The primary objective of this study is to present a case series of balloon dilation treat-
ment for post-transplantation ureteral strictures and to determine its success-rate. The 
secondary objective is to determine which factors might be of influence on the outcome 
of balloon dilatation.
Methods
Patients
The Medical Ethical Committee approved the trial protocol (MEC-2015-119).The hospital 
database of the Erasmus Medical Center (EMC), Rotterdam, and the Academic Medical 
Center(AMC), Amsterdam, were screened for patients that underwent radiological bal-
loon dilatation of the ureter after KT. Baseline characteristics included recipient gender 
and age, type of donor (deceased vs. living), second warm ischemic time (WIT), cold 
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ischemic time (CIT), technique for ureteroneocystostomy (intravesical vs. extravesical), 
number of prior transplantations, months between KT and balloon dilatation, stricture 
characteristics, readmissions within 1 month after balloon dilatation and follow up in 
months after balloon dilatation. Balloon dilatation was considered technically successful 
if the interventional radiologist could pass the strictured segment with the guidewire 
and the balloon could be inflated. Balloon dilatation was clinically successful if no 
further interventions, for instance surgical revision of the ureterneocystostomy or later 
prolonged double J placement, were necessary. Graft survival was based on the date a 
patient returned to hemo- or peritoneal dialysis or received a pre-emptive new trans-
plant. All complications that occurred within 30 days after balloon dilatation and lead to 
a readmission, were documented.
Diagnosing ureteral stricture
For all patients presented with increased serum creatinine and hydronephrosis on ul-
trasound, percutaneous nephrostomy (PCN) placement was the first step in treatment. 
Using anterograde pyelography, the diagnosis of ureteral stricture was confirmed. 
For this study, all pyelograms were analyzed retrospectively for location of the ureter 
stricture (proximal, mid-ureteral, distal, total or multiple) and length of the stricture by 
1 interventional radiologist (AM) with over 8 years of experience in urogenital interven-
tions. If the ureter had multiple strictured segments the length of the longest stricture 
was documented.
Balloon dilatation procedure
The nephrostomy tube was replaced by a 8 French vascular sheath and a 4 French cath-
eter with a hydrophilic 0.035” guidewire (Terumo, Belgium) was introduced through the 
sheath into the renal pelvis and ureter in antegrade fashion. The guidewire was then 
passed through the strictured segment of the ureter into the bladder and a 3 to 8 mm 
diameter balloon was advanced over the guidewire and inflated during several minutes. 
In cases where traversing the stricture was difficult, smaller diameter wires (0.014”) and 
balloons could be used. The type of balloon varied over time between a regular and a 
cutting balloon up to the discretion of the treating interventional radiologist. The cut-
ting balloon has three or four microsurgical blades. These blades are fixed longitudinally 
on the outer surface of the balloon, expand radially and deliver longitudinal incisions 
in the strictured segment of the ureter. After deflation of the balloon, either a PCN, a 
nephroureterostomy catheter (PCNU, figure 1) or a double J catheter was placed.
Statistical analyses
Categorical variables are presented as numbers (percentage). Continuous variables are 
presented as median (range) if not normally distributed; continuous variables with nor-
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mal distribution are presented as means with standard deviation. Normality was based 
on the shape of the histogram plot and tested with the Shapiro-Wilk test. Categorical 
variables are analyzed using the Chi-square test. Continuous variables are analyzed 
using the Mann-Whitney-U test or an independent T-test. Graft survival is analyzed us-
ing a log rank test and is censored for death. For graft survival we did not distinguish 
between technically or clinically successful balloon dilatations. All technically and clini-
cally unsuccessful balloon dilatations were considered as unsuccessful. All analyses were 
conducted using IBM SPSS Statistics for Windows (version 21.0. Armonk, NY: IBM Corp, 
USA). A p-value <0.05 (two-sided) was considered statistically signifi cant.
Results
Baseline characteristics
A total of 50 patients underwent antegrade balloon dilatation (table 1). This included 
37 (2.5 %) patients of 1496 kidney transplants that were performed in the Erasmus MC 
between August 2007 and September 2015. Thirteen (2.2%) patients underwent balloon 
dilatation out of the total of 579 kidney transplantations performed in the AMC. The 
AMC included patients for this study within a shorter period, being from March 2011 un-
til June 2015. Median time between KT and balloon dilatation treatment was 3 months 
(range, 0-139). The median length of the total strictured segment was 2 (0.5-5) cm and 
median follow up after balloon dilatation was 35.5 (0-102) months.
Figure 1. Balloon dilatation and PCNU catheter
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Balloon dilatation
In 43 of 50 (86%) patients balloon dilatation was performed successfully from a technical 
point of view, whereas in 7 (14%) patients it was impossible to pass the strictured seg-
ment with the guidewire. Out of the 7 patients of whom the stricture was impossible to 
pass, two patients had a second and even a third attempt for balloon dilatation. These 
all remained technically unsuccessful. In 20 of the 43 (47%) patients who underwent 
a technically successful balloon dilatation, the procedure was also clinically successful. 
Median follow up after balloon dilatation was 35.5 months (0-102). In 12 patients bal-
loon dilatation was clinically successful after one attempt, 7 patients needed a second 
Table 1. Baseline characteristics
Characteristic Total patients N=50
Gender: Male N (%) 30 (60)
Age at KT mean ± SD years 48 ± 16
Type donor: Living N (%) 35 (70)
WIT 2 in minutes median (range) 26.5 (13-80)
CIT in minutes median (range) 169 (96-2520)
Type anastomose
Intra N (%) 10 (20) 
Extra N (%) 34 (68) 
Not documented N (%) 6 (12) 
Primary reason PCN
Hydronephrosis N (%) 43 (86) 
Urinary leakage N (%) 7 (14) 
Number transplant median (range) 1 (1-4)
Months between KT and BD median (range) 3 (0-139)
Length longest stricture in cm median (range) 1.5 (0.5-5)
Length total stricture in cm median (range) 2 (0.5-5)
Location stricture
Distal N (%) 33 (66) 
Proximal N (%) 3 (6) 
Mid-ureteral N (%) 2 (4) 
Total N (%) 6 (12) 
Multiple N (%) 6 (12) 
Number of BD median (range) 1 (1-4)
Technical successful balloon dilatation N (%) 43 (86)
Clinical successful (of technically successful) BD N (%) 20 (47)
Follow up in months after BD median (range) 35.5 (0-102)
N, number; KT, kidney transplantation; cm, centimeter; SD, standard deviation; BD, balloon dilatation; WIT, 
Warm Ischemic Time; CIT, Cold Ischemic Time; Intra, intravesical; Extra, extravesical
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treatment and one patient needed 4 balloon dilatation treatments before success was 
reached. These additional balloon dilatation were during a repeat procedure and not in 
the same procedure.
One patient with a technically successful dilatation died from a pneumosepsis (pneumo-
cystis jiroveci) 1 month after balloon dilatation. This was prior to stent removal; there-
fore, we were not able to determine whether balloon dilatation was successful. Another 
patient had a severe graft rejection after balloon dilatation and graft nephrectomy was 
necessary. In this case, we were also not able to determine the success of balloon dilata-
tion. Therefore, in these two patients the success was scored as missing. One patient 
had a kidney infarction after balloon dilatation and this was scored as unsuccessful. This 
event will be discussed further below in the complications section.
Two patients underwent a surgical revision of the ureterocystostomy prior to a success-
ful balloon dilatation. One of these patients received her transplant in 2003 and had a 
surgical revision of the ureteroneocystostomy in 2004. During this period, we did not 
carry out balloon dilatations yet in our hospital. In 2014, this patient had a recurrent 
stricture and underwent successful balloon dilatation. The other patient had urinary 
leakage primarily followed by a surgical ureteral reconstruction 2 days after transplan-
tation. This patient developed a stricture which was successfully treated with balloon 
dilatation.
Of the patients who underwent technical successful balloon dilatation (n=43) a regu-
lar balloon was used in 36 patients and a cutting balloon in 7 patients. In 40 patients 
the strictured segment was stented post-balloon dilatation with a PCNU catheter or a 
double J catheter and in 3 patients a regular PCN was placed and therefore scored as 
non-stented.
Twenty-six patients underwent surgical repair after a balloon dilatation attempt. In 16 
patients the strictured segment was resected and a new ureteroneocystostomy was 
made. In 4 patients the native ureter was attached to the transplant pyelum, 3 patients 
had a pyelocystostomy and in 1 patient the native ureter was attached to the transplant 
ureter. During surgical exploration in 1 patient the total ureter was strictured and no 
further surgical options were available. This patient remained nephrostomy dependent. 
In the last patient no ureteral obstruction was objectified during surgical exploration, 
however a very limited bladder capacity was detected and this patient was treated with 
a suprapubic catheter.
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Complications
In one patient a kidney infarction was diagnosed 22 days after balloon dilatation treat-
ment and 13 days after PCN replacement. As kidney function deteriorated, a biopsy 
was performed to exclude rejection. Renal failure was attributed to loss of parenchymal 
tissue secondary to infarction due to vascular damage. The complication was not at-
tributed to balloon dilatation as such. However, the intervention procedure was scored 
as clinically unsuccessful in this case series.
One patient developed a ureter stricture 
of 1,5cm in the distal part of the ureter 3 
months after transplantation. A PCN was 
placed and a pyelogram was made to visual-
ize the pyelo-ureteral anastomosis. During 
this procedure, a fi stula between the pyelum 
and iliac vein was visualized (Figure 2). It is 
unknown whether it was present before or 
caused by the intervention. The antegrade 
balloon dilatation procedure was ended 
prematurely, i.e. before entering the bladder 
with the guidewire; no ureteral dilatation 
was performed. In the hours following the 
procedure the patient developed a septic 
shock and died despite antibiotic treat-
ment. The cause of death was explained by 
bacteremia due to direct circulatory contamination with a multi-resistant E.coli in an 
immunocompromised patient.
There were 23 patients without complications that lead to readmission. Eighteen 
patients were readmitted within one month because of urosepsis. These readmissions 
could also cohere with chronic contamination due to continue PCNU or PCN placement 
requiring a replacement of the PCNU or PCN. One patient was readmitted because of the 
previously mentioned kidney infarction, 1 patient was readmitted because of hematuria 
with creatinine rise caused by an obstructive blood cloth, 1 patient was readmitted with 
a deep venous thrombosis, 2 patients were readmitted in order to treat additional rejec-
tion, 3 patients were admitted because of PCN related complications (urinary leakage 
or dislocation) and 1 for diarrhea followed by urosepsis and surgical revision of the ure-
teroneocystostomy, again all within the 30 days period. In this last patient a perforation 
of the ureter occurred while the radiologist tried to pass the strictured segment with 
Figure 2. Pyelo-venous fi stula 
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the guidewire. It was impossible to pass the strictured segment and the procedure was 
ended prematurely.
Graft survival 
Graft survival after successful balloon dilatation was 100% at 12 months and 75% at 24 
months after balloon dilatation. For the unsuccessful procedures graft survival was 92% 
at 12 and 24 months after attempting the balloon dilatation, P=0.937 (Figure 3). Grafts 
failed due to several causes, such as 3 chronic failures followed by pre-emptive retrans-
plantation in 2 patients, 2 acute rejections, the previously mentioned kidney infarction, 
1 recurrent primary disease (focal segmental glomerulosclerosis), 1 glomerulosclerosis 
and interstitial fi brosis, 1 cardiac shock with subsequent contrast overload lead to acute 
tubulus necrosis and in 1 patient due to urosepsis.
Figure 3. Graft survival after balloon dilatation
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Risk factor analysis
In univariate analysis, we found that neither donor characteristics (type donor, WIT, CIT), 
type of ureteroneocystostomy technique, recipients gender, months between KT and 
balloon dilatation, type and diameter of the balloon used, stricture length, stricture 
location nor the use of a stent after balloon dilatation were factors that could influence 
the outcome of the treatment (table 2).
Table 2. Factors that might contribute to clinical success of technically successful balloon dilatation (N=2 
outcome is missing)
Factor Unsuccessful clinical 
balloon dilatation 
(N=21)
Successful clinical 
balloon dilatation 
(N=20)
P-value
Extravesical technique ureteroneocystostomy N (%) 16 (84) 12 (71) 0.326
Gender recipients Male (N%) 14 (67) 10 (50) 0.279
Type of donor living N (%) 14 (67) 16 (80) 0.335
WIT 2 in minutes median (range) 24 (14-80) 25.5 (13-56) 0.886
CIT in minutes median (range) 180 (96-1860) 156 (114-1260) 1.000
Length longest stricture in cm median (range) 1.7 (0.5-5) 1.5 (0.5-5) 0.439
Longest stricture > 3cm N (%) 5 (24) 2 (10) 0.240
Months between KT and BD median (range) 3 (0-139) 3 (0-135) 0.484
>3months between KT and BD N (%) 8 (38) 8 (40) 0.901
Location stricture
- Total N (%) 2 (10) 1 (5) 0.562 
- Proximal N (%) 2 (10) 1 (5)  
- Distal N (%) 12 (57) 15 (75)  
- Mid-ureteral N (%) 2 (10) 0 (0)  
- Multiple (%) 3 (13) 3 (15)  
Type balloon
- Cutting N (%) 4 (19) 3 (15) 0.731 
- Regular N (%) 17 (81) 17 (85) 
Diameter balloon
- 3-4 mm N (%) 4 (19) 3 (15) 0.942 
- 5-6 mm N (%) 7 (33) 7 (35)  
- 7-8 mm N (%) 10 (48) 10 (50)  
Stented post dilatation N (%) 20 (95) 18 (90) 0.520
Univariate analysis. Cm, centimeters; KT, kidney transplantation; BD, balloon dilatation; SD, standard devia-
tion; WIT, Warm Ischemic Time; CIT, Cold Ischemic Time 
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Discussion
Urological complications as urinary leakage and ureteral strictures may occur as early 
as well as late complications after kidney transplantation. In this study, we analyzed the 
outcome of balloon dilatation as treatment for ureter strictures after kidney transplan-
tation. The technical success-rate was 86% and the subsequent clinical success-rate of 
balloon dilatation treatment was 47%. We could not identify any factors that may have 
contributed to a (non)successful outcome of a balloon dilatation.
Several other studies report on the outcome of balloon dilatation. Asadpour et al. report 
on 24 patients with ureteral strictures of whom 11(46%) had a successful outcome after 
balloon dilatation and PCN treatment 8 and there results are comparable to the outcome 
of the present study. Aytekin et al. report a balloon dilatation success-rate of 90% in 
their cohort of 10 patients with late obstructions due to strictures, which is a higher 
success-rate than our cohort. Four patients had a recurrence of the stricture, and there-
fore repeated balloon dilatation was necessary. In 2 of these patients a metallic stent 
was placed. In only 1 patient surgical revision of the ureterocystostomy after balloon 
dilatation was necessary. It should be noted that in this study a 7-Fr double J catheter 
was inserted as standard care after balloon dilatation. This might have increased their 
success-rate 9. On the other hand Juaneda et al. report on 45 patients with ureteral 
strictures with a 45% success-rate while placing a double J catheter after all balloon 
dilatations as well 10.
He et al. tried to define a management strategy for kidney transplant recipients who 
developed a ureteral obstruction. In their study they define 3 grades of ureteral stric-
tures; Grade 1) hydronephrosis without an evidently strictured segment, Grade 2) 
hydronephrosis with ≤1 cm strictured segment, and Grade 3) hydronephrosis with 
>1 cm strictured segment 11. They propose the following treatment options; Grade 1) 
prolonged stent insertion for 6 weeks, Grade 2) cystoscopy with incision or balloon 
dilatation followed by stent insertion for 6 weeks, Grade 3) Surgery. When we apply this 
classification and management strategy on our cohort, 17 patients would fit the grade 
2 classification, in 9 of these patients balloon dilatation was successful. In our cohort 33 
patients have a stricture that can be classified as grade 3 and would therefore benefit 
from surgical treatment. However, 11 of these patients had successful balloon dilatation 
and would have been subjected to unnecessary surgical intervention when following 
this classification 11. Based on our cohort we would advise to perform a balloon dilata-
tion prior to surgical revision, as it is less invasive, irrespective of the proposed grading 
system.
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There are some limitations to this study. Even though our study includes the highest 
number of balloon dilatations reported until now, the number of 50 patients remains 
low. Therefore, analyses for factors that could contribute to the success-rate of balloon 
dilatation treatment cannot be performed reliably or maybe none of the factors does in-
fluence the outcome. Furthermore, our post-balloon dilatation treatment was different 
in our patients. In some of them the PCN drain was left in situ and in others the PCN was 
removed and a single pigtail in PCNU position or a double J catheter was placed instead. 
Based on the available literature double J catheter placement has a favorable outcome, 
however this would indicate an additional cystoscopy would be necessary to remove 
the double J catheter 9,11. A drain in PCNU position would give the benefit of a stented 
stricture post-dilatation treatment and would lack the risks of an additional cystoscopy.
We believe that balloon dilatation should be advocated as the first treatment for ureter 
strictures. It is clinical successful in 47% of the patients and it is less invasive than open 
surgical ureter reconstruction.
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Abstract
The aim of this study was to evaluate the number of urinary tract infections (UTI) that 
occur after kidney transplantation (KT) and to identify possible risk factors for develop-
ment of a UTI. For this study, we retrospectively analysed all KTs that were performed 
between January 2012 and December 2013 in the Erasmus University Medical Center, 
Rotterdam. UTI was scored if: a patient had a urine culture with no more than two spe-
cies of microorganisms, second, with at least one of which was a bacterium of ≥ 10^5 
CFU/mL, third which was treated with antibiotics and fourth, which occurred within 3 
months after KT. A total of 417 patients were transplanted from January 2012 until De-
cember 2013. One hundred and fifteen (28%) developed a UTI, after a median of 13 days 
from transplantation (range: 3-82). The most common causative agent was Escherichia 
coli, followed by Enterococcus faecalis, Enterococcus faecium and Klebsiella pneumoniae. 
The variables that were independently related to a UTI were female gender (OR 3.58, 
95%CI 2.16-5.91), recipients age >60y (OR 2.12, 95%CI 1.28-3.48), percutaneous neph-
rostomy placements (OR 6.29, 95%CI 3.35-11.85) and surgical re-interventions (OR 2.12, 
95%CI 1.04-4.32). Mean glomerular filtration rate was significantly lower in the group of 
patients with a UTI at 3, 6, 9 and 12 months postoperatively compared to those patients 
who did not have a UTI. We conclude that a UTI after KT is a common problem. We identi-
fied independent risk factors for the development of a UTI. UTI is associated with a GFR 
decrease postoperatively.
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Introduction
Kidney transplantation (KT) is the best and most cost-effective treatment for patients 
with end stage renal disease. It improves overall survival rates and quality of life of 
patients compared to patients on chronic dialysis (1). Preventing complications that 
comprise graft outcome remains a challenge in KT.
Infections are a common problem in patients receiving immunosuppressive treatment 
after transplantation (2). Urinary tract infections (UTI) after KT are reported up to 38% 
(3). For example, Bodro et al. reported an incidence of 184 UTI (21%) out of 867 KT 
recipients with a median of 18 days from transplantation (4). Furthermore, acute graft 
pyelonephritis is mentioned up to 15% and an association with kidney graft impairment 
and graft loss has been reported (4, 5).
Risk factors for the development of a UTI after KT are prolonged hospital stay and a 
high body mass index (BMI) (6). Furthermore, independent risk factors are shown to be 
female gender, recurrent UTI before transplantation, acute rejection, induction therapy 
(either anti-thymocyte globulin or basiliximab) and cytomegalovirus infection (7).
In this study, we retrospectively analyzed the data of 417 KTs performed in our center 
between January 2012 and December 2013, to evaluate the number of UTI in the first 
3 months after transplantation. Additionally, we aimed to identify risk factors that 
were related to the development of UTI and we investigated whether a UTI in the first 
3 months after transplantation compromised graft function within the first 12 months 
after transplantation.
Methods
Study population and data selection
In this study we included all KT recipients (>18yrs) operated at the Erasmus University 
Medical Center between January 2012 and December 2013, independent of a recon-
structed urinary tract (i.e. Bricker bladder) or UTI prior to transplantation. Pediatric 
KT recipients were excluded from this study. Baseline data of the recipients included 
gender, age, ethnicity, ASA classification, type of donor, number of previous transplanta-
tions, HLA-mismatches, ABO-incompatible KT, BMI, diabetes, technique for ureteroneo-
cystostomy (intra- vs. extravesical), warm and cold ischemia time, duration of surgery, 
per-operative blood loss, pre-emptive transplantation (prior to start dialysis), use of 
ureterovesical stent, percutaneous nephrostomy placements (PCN) < 3 months after KT, 
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biopsy proven rejection en subsequent treatment <3 months, surgical re-intervention 
< 3 months after KT and hospital admittance days of initial admission. Follow-up for 
our primary outcome (UTI) was performed until 3 months after KT. For our secondary 
outcome (graft function) follow up was performed until 12 months after KT. The medical 
ethical committee of the Erasmus University medical center approved this study proto-
col (MEC-2016-279).
Urinary tract infection
For the definition for UTI we used adjusted Center of Disease Control (CDC) definitions 
(8). UTI was scored if firstly a patient had a urine culture with no more than two species 
of microorganisms (CDC). Second, with at least one of which was a bacterium of ≥ 10^5 
CFU/mL (CDC), third which was treated with antibiotics (non-CDC) and fourth, which oc-
curred within 3 months after KT (non-CDC). Antibiotic treatment was started when the 
patient had one of the following symptoms: fever>38°C, suprapubic tenderness, urinary 
urgency/frequency, transplant tenderness and dysuria. During the primary admission 
for the transplantation, urinary cultures were collected every Monday, Wednesday and 
Friday. After discharge, urinary cultures were not collected in a standardized manner 
and frequency, as they were only taken by the above mentioned clinical indications. All 
first UTI that arose within 3 months after transplantation were included in this study, 
all recurrent UTI in the same patient were not scored as separate events. All patients 
received a surgical prophylaxis with cefazolin 3*1000mg intravenous on the day of 
surgery. Postoperatively a prophylaxis to prevent a Pneumocystis carinii pneumonia of 
480mg trimethoprim/sulfamethoxazole was given orally once a day until 3 months after 
KT. To prevent cytomegalovirus (CMV) infections, a prophylaxis of valganciclovir was 
given the first 6 months after transplantation, unless both the donor and recipient were 
CMV negative. Dosage of valganciclovir was dependent on GFR: 1) if GFR> 40 ml/min: 
450mg once a day 2) if GFR: 25-39ml/min: 450mg every other day 3) if GFR <25ml/min : 
450mg twice a week.
Surgical technique
During surgery, the kidney was placed in the extra peritoneal iliac fossa. After the vas-
cular anastomoses on the external iliac vessels, the surgeon performed either an intra-
vesical anastomosis described by Politano-Leadbetter (9) or an extravesical anastomosis 
described by Lich-Gregoir (10, 11). An externalized ureterovesical stent was placed as 
standard care (excluding some patients with residual native urine production, about 
7%) and it was removed 9 days postoperatively. A transurethral urinary bladder catheter 
was removed after 7 days. In the cause of a urinary leakage or a ureter stenosis (resulting 
in hydronephrosis) a PCN was placed postoperatively.
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Immunosuppressive treatment
Immunosuppressive treatment consisted of basiliximab intravenous on the day of sur-
gery and day 4 after transplantation. Postoperative immunosuppression consisted of 
tacrolimus, mycophenolate mofetil and prednisolone. The prednisolone was tapered off 
to be discontinued at 4 months after transplantation.
Statistical analysis
All analyses were conducted using IBM SPSS Statistics for Windows (version 21.0. Ar-
monk, NY: IBM Corp, USA). A p-value of <0.05 (two-sided) was considered statistically 
significant. Continuous variables were presented as means with standard deviations if 
normally distributed or as median with range if not normally distributed. These variables 
were analysed using the independent T-test or the Mann-Whitney U test. Categorical 
variables were presented as numbers with percentages and were analysed using Chi-
square test. We performed multivariate analysis using logistic regression and included 
covariates with p-values <0.05 in univariate analysis. The analysis was two-tailed and 
results were presented as odds-ratios (OR) with 95% confidence intervals (95% CI).
Results
Baseline characteristics
Between January 2012 and December 2013 417 adult (>18yr) KT were performed in 
our center. Mean age of this cohort was 55±14 years and included 261 (63%) males and 
156 (37%) females. The most common ethnicity was caucasian (79%), most KT involved 
living donors (67%) with a median cold ischemia time of 158 (89-1576) minutes and a 
warm ischemia time of mean 23±8 minutes. One hundred and fifteen patients out of a 
total of 417 patients (28%) developed UTI, after a median of 13 days from transplantation 
(range: 3-82). Most UTI occurred within the first 20 days after KT, N=74 out of 417 (18%) 
(figure 1). There were no differences in recipients with UTI and those without UTI with 
respect to ASA-classification, type of donor, number of transplant, HLA mismatches, ABO-
incompatible transplantation, BMI, pre-emptive transplantation, diabetes, technique for 
ureteroneocystostomy (intra vs extra), stent usage, warm and cold ischemia time, duration 
of surgery, per-operative blood loss, and biopsy proven rejection within 3 months after 
transplantation. Then again, univariate analysis did show that UTI was related to female 
gender, higher age, age>60y, non-caucasian ethnicity (i.e. Asian/African-American) PCN 
placements < 3 months after KT, more surgical re-interventions and prolonged initial 
hospital stay (Table 1). Thirty-seven out of 60 patients with a PCN placed within 3 months 
after KT developed a UTI < 3 months after KT. Eleven of these developed a UTI prior to PCN 
placement and 26 patients developed a UTI after PCN placement.
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Causative agent
Out of 417 patients a total of 4559 urinary cultures were taken within 3 months after KT. 
This implies that in individual patients a mean of 11±6 urinary cultures were collected. 
From the urinary cultures of the 115 patients with a UTI, the microorganism most com-
monly identifi ed was Escherichia coli (n=50), followed by Enterococcus faecalis (n=28), 
Enterococcus faecium (n=8), Klebsiella pneumoniae (n=8), Pseudomonas aeruginosa (n=6), 
Klebsiella oxytoca (n=4), Proteus mirabilis (n=3), Acinetobacter spp. (n=3), Citrobacter spp 
(n=3), Pseudomonas fl uorescens (n=2), Pseudomonas putida (n=2), Enterobacter cloacae 
(n=2), Morganella morganii (n=2), and single cases of Aeromonas caviae, Candida krusei, 
Escherichia spp, Pseudomonas spp, Staphylococcus epidermidis, Staphylococcus aureus, 
and Streptococcus agalactiae. In urinary cultures of 13 out of 115 patients (11.3%), 2 dif-
ferent microorganisms were identifi ed.
Risk factor analyses
In univariate analyses female gender, age, number of PCN, surgical re-interventions, 
non-caucasian ethnicity and initial hospitalisations days were diff erent between patients 
who developed a UTI with P values <0.05. We included these variables in the multivari-
ate analysis. The variables that were independently related to a UTI were female gender, 
Figure 1. Incidence of UTI after KT
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recipients age >60y, PCN placements and surgical re-interventions (Table 2). Excluding 
patients who already had a UTI prior to PCN placement (N=11) in the same multivariate 
model, would still result in a signifi cant OR of 4.52 (95%CI 2.31-8.83, p<0.001) for PCN 
placement as an independent risk for UTI.
Table 1. Demographic and clinical characteristics
Characteristic No UTI (302) UTI (115) P-value
Gender recipient male N (%) 210 (70) 51 (44) <0.001
Age recipient in years mean ± SD 54±14 58±13 0.007
Age > 60y N (%) 111 (37) 61 (53) 0.003
Ethnicity N (%)
Caucasian 245 (81) 83 (72) 0.046 
Non-caucasian 57 (19) 32 (28)  
ASA N (%) 0.700
2 56 (19) 26 (23)  
3 237 (80) 88 (76)  
4 3 (1) 1 (1)  
Living Donor N (%) 205 (68) 76 (66) 0.727
Number transplant N (%)
 
 
1 247 (82) 1 91 (79) 0.680
2 40 (13) 2 19 (17)  
≥3 15 (5) ≥3 5 (4)  
HLA-MM median (range) 3 (0-6) 4 (0-6) 0.950
ABO incompatible N (%) 14 (5) 7 (6) 0.545
BMI recipient mean ± SD 26±5 27±5 0.144
Pre-emptive KT N (%) 109 (36) 37 (32) 0.453
Diabetes N (%) 74 (25) 33 (29) 0.381
Extravesical technique N (%) 225 (87) 81 (80) 0.076
Stent Yes N (%) 281 (93) 106 (92) 0.672
Biopsy proven rejection <3 months N (%) 39 (13) 15 (13) 0.972
Cold ischemia minutes time median (range) 157 (89-1576) 159 (110-1380) 0.751
Warm ischemia 2 minutes time mean ± SD 23±8 22±7 0.837
Duration of surgery minutes mean ± SD 141±38 141±45 0.972
Blood loss in mL median (range) 250 (0-3600) 300 (0-3000) 0.053
PCN placement < 3 months N (%) 23 (8) 37 (32) <0.001
Surgical re-intervention < 3 months N (%) 24 (8) 23 (20) 0.001
Initial hospital admittance days median (range) 12 (5-65) 15 (7-122) <0.001
UTI; urinary tract infection; N, number; SD, standard deviation; KT, kidney transplantation; BMI, body mass 
index; PCN, percutaneous nephrostomy; ASA, American Society of Anesthesiologist physical status clas-
sifi cation
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Graft function
Mean glomerular filtration rate (GFR) was significantly lower in patients who developed 
a UTI at 3, 6, 9 and 12 months after transplantation compared to patients who did not 
develop a UTI (Table 3).
Discussion
In this analysis, we identified 115 out of 417 patients (28%) who developed a UTI after 
KT. In multivariate analysis, variables that were independently related to the develop-
ment of UTI were female gender, recipients’ age>60y, PCN placement and surgical re-
interventions within 3 months after transplantation. Mean GFR at 3, 6, 9 and 12 months 
after transplantation was significantly lower in patients who had a UTI compared to 
those who did not have a UTI.
Female gender has previously been associated with the development of UTI, both in the 
normal population as in kidney recipients (12). The risk for UTI after placement of a PCN 
could be explained due to the additional port d ’entrée. Incidence of UTI in non-trans-
plant patients with PCN are reported by Kaskarelis et al. with 0.87% UTI in 341 patients 
(13). This number seems to be much higher in transplant patients as the total number of 
Table 2. Multivariate risk factor analysis
Risk factor Odds ratio 95% CI P-value
Female gender 3.58 2.16-5.91 <0.001
Age > 60y 2.12 1.28-3.48 0.003
PCN < 3 months after KT 6.29 3.35-11.85 <0.001
Surgical re-intervention < 3 months 2.12 1.04-4.32 0.038
Initial hospitalisation days 1.02 0.99-1.05 0.148
Non-caucasian ethnicity 1.75 0.99-3.08 0.051
CI, 95% confidence intervals; PCN, percutaneous nephrostomy; KT; kidney transplantation
Table 3. Graft function
Characteristic Total (417) No UTI (302) UTI (115) P-value
GFR mL/min 1 month after KT mean ± SD 46± 17 47± 17 43 ±18 0.061
GFR mL/min 3 months after KT mean ± SD 47± 15 48± 15 43± 16 0.005
GFR mL/min 6 months after KT mean ± SD 48± 16 49± 16 44± 17 0.005
GFR mL/min 9 months after KT mean ± SD 48± 16 49±16 45± 17 0.010
GFR mL/min 12 months after KT mean ± SD 48± 16 50±16 43± 16 <0.001
GFR, glomerular filtration rate; UTI, urinary tract infection; KT, kidney transplantation; SD, standard devia-
tion
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PCN placed within 3 months after KT in our cohort was 60 patients of whom 26 patients 
(43%) developed a UTI after PCN placement. PCNs were placed if a urinary leakage or a 
stenosis of the ureter (resulting in hydronephrosis) occurred post-operatively. Instead 
of PCN placement, an alternative treatment option for these urological complications is 
direct surgical repair. However, in a previously conducted RCT at our center (INEX-trial) 
only 10 out of 40 patients with a PCN placement required a re-intervention (such as a 
surgical revision or a balloon dilatation) (14), saving 30 patients from revision. Therefore, 
direct surgical re-invention in case of urological complications would be excessive. 
Minimizing the number of urological complications and thus PCN placement remains 
one of the challenges in KT.
There was a significant decrease in mean GFR in patients after developing a UTI com-
pared to those who did not. This finding is complimentary to the results of Bodro et al 
(4). In a review of Martin-Gandul et al. the impact of UTI on graft function appears to be 
different according to the period of the onset of the infection (early vs. late). They found 
that late and recurrent UTI only seem to be related to an increased risk of graft dysfunc-
tion, this is in contrast to our results (15). It should be noted that the GFR outcome on 6, 
9 and 12 months can be influenced by several factors. In our analyses, we only included 
events (rejection, UTI) that occurred within the first 3 months after transplantation. 
Furthermore, there were more non-caucasian patients (28% vs 19%) in the UTI group. 
We have used GFR data without correcting for African-American origin. This could also 
contribute to a lower GFR in the UTI group. Therefore, we suggest that the association 
between UTI and decreased GFR should be taken with caution.
In a Cochrane review by Lusardi et al. the use of antibiotics prophylaxis for short term 
catheter bladder drainage (≤14 days) in adults was discussed (16). They conclude that 
antibiotic prophylaxis, compared to treatment with antibiotics when microbiologically 
indicated, reduced the rate of bacteriuria in general surgical patients when a urinary 
catheter is placed for at least 24 hours (16). As KT recipients receive high dose immuno-
suppression, the use of a prophylaxis is emphasized by Wolters et al.(17). They suggest 
250mg of ciprofloxacin twice daily 1 day before and at the day of the removal of the uri-
nary catheter (17). This finding is supported by a meta-analysis of Marschall et al. stating 
that patients admitted to the hospital who undergo short term urinary catheterization 
(< 14 days) might benefit from antimicrobial prophylaxis; a drawback of this article for 
our cohort is that the patients included were no KT recipients. Ciprofloxacin and trim-
ethoprim/sulfamethoxazole were the most commonly used antibiotics for prophylaxis 
in their meta-analysis (18). In our cohort of KT recipients with a UTI, we found that 24% 
of tested Enterobacteriaceae were resistant to ciprofloxacin and 86% to trimethoprim/
sulfamethoxazole; therefore, antibiotic prophylaxis using these two antibiotics is not 
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effective. Additionally, other microorganisms identified (e.g. Enterococci and Staphy-
lococci) are intrinsically resistant to ciprofloxacin. Therefore, we purpose culture-based 
prophylaxis for KT recipients.
In our center an externalized stent and a urinary bladder catheter are placed during 
transplantation and removed on respectively day 9-10 and day 7 after transplantation, 
both without antibiotic prophylaxis. We identified age>60y and female gender as sepa-
rate and independent risk factors for the development of a UTI. It may be advocated 
to remove the stent in patients with these risk factors with an antibiotic prophylaxis, 
although there is no strong evidence for this approach. A well-designed prospective 
randomized controlled trial in KT recipients with an externalized stent could provide the 
answer to this subject.
One of the limitations of our study is the fact that this is a retrospective study. The 
symptoms of UTI were not well documented and therefore we were not able to use the 
full CDC criteria and thus we choose to include those patients who received antibiotic 
treatment for UTI. Furthermore, there are a few symptoms included in the CDC criteria, 
such as costovertebral angle pain or tenderness and urinary urgency/frequency, which 
are not always relevant to transplant recipients. Since the kidney transplant is in the iliac 
fossa and some transplant recipients have no residual urine production and therefore 
have limited bladder capacity resulting in urinary urgency and frequency without a 
UTI. Another drawback of this study was that urinary cultures were not collected in a 
standardized manner and frequency after discharge, only during the primary admission 
every Monday, Wednesday and Friday standard urinary cultures were collected, after 
discharge they were only taken by clinical indication.
We conclude that UTI after KT is a common problem (28%). E. coli and E. faecalis are 
the most causative agents. We identified female gender, age>60y, PCN placement and 
surgical re-interventions as independent risk factors for the development of UTI after KT. 
UTI is associated with a decrease in mean GFR at 3, 6, 9 and 12 months postoperatively. 
Further studies are needed to resolve these severe complications in these high-risk pa-
tients. Studies on removing the catheter or stent under antibiotic prophylaxis are now 
urgently needed.
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Abstract
Urological complications after kidney transplantation, such as urinary leakage and 
ureteral strictures, are associated with significant morbidity, surgical or radiological re-
interventions, prolonged hospital stay and even mortality. It has been demonstrated 
that stent placement can minimize the number of urological complications. Two types 
of ureteral stents can be used; mainly divided in internal double J stents and external 
single J stents. It is unknown which kind of stent is superior in preventing urological 
complications. Therefore, in this study we will investigate whether double J stenting is 
superior to the use of an external stent in reducing the number of urological complica-
tions after kidney transplantation.
This will be a single-centre randomized controlled trial. Randomization will be per-
formed after intubation in the operation room. All adult kidney transplant recipients 
that will be transplanted at the Erasmus University Medical Center (>18yrs) are invited 
to participate. Patients will be excluded if they do not understand the Dutch language 
sufficiently to sign the informed consent forms and to fill in the questionnaires, or if they 
have a reconstructed urinary tract or conduit after total or partial cystectomy, a bladder 
dysfunction that requires continuous or intermittent catheterization, or will receive a 
donor kidney with more than one ureter. In addition, patients with primary FSGS and 
residual urine production will be excluded. Nowadays, our clinical practice is the use 
of an external stent during kidney transplantation. Our “intervention” will be the use 
of an internal double J stent which will be removed by cystoscopy 3 weeks after trans-
plantation. Our main study endpoint is the number of percutaneous nephrostomy (PCN) 
drainages. The secondary study parameters are urinary tract infections, macroscopic 
haematuria, radiological interventions, surgical re-interventions and stent obstruction 
or dysfunction. Furthermore, we will ask the recipients to fill in questionnaires to analyse 
the quality of life and make a cost-effectiveness analysis.
The DUET-trial will provide evidence about which type of stent (double J vs. external) 
should be used during kidney transplantation to minimize the number of urological 
complications.
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Introduction
Kidney transplantation is the best treatment offering long-term benefit to patients with 
chronic kidney failure. Urological complications after kidney transplantation, such as uri-
nary leakage and ureteral strictures, are associated with significant morbidity, surgical or 
radiological re-interventions, prolonged hospital stay and even mortality. Many urologi-
cal complications are related to the ureteroneocystostomy and the first treatment for 
urinary leakage or ureteral stenosis is placement of a percutaneous nephrostomy (PCN) 
drain(1, 2). It has been demonstrated that stent placement can minimize the number of 
urological complications (3, 4). Two types of ureteral stents can be used; mainly divided 
in internal double J stents and external single J stents. In our center, we have used an 
external stent for several years and urological complications are reported up to 9% of 
the kidney transplant recipients (5). However, in literature several studies even report 
less urological complications using a double J stent. A retrospective study by Vogel et 
al. including 76 patients with 43 external stents and 33 double J stents have reported an 
incidence of leakage of the ureteroneocystostomy of 13.9% in the external stent group 
compared to 0% in the double J stent group. Furthermore, they found a 2 day reduction 
of hospital stay with a double J stent (6). Gomes et al. also retrospectively reviewed the 
use of external, double J stents and no stents in 2061 kidney transplant recipients. In their 
cohort, urological complications occurred in 17.3% in the group with external stents, 
8.4% in patients that did not receive a stent, and 5.4% in kidney transplant recipients in 
whom a double J stent was placed (P < .0005)(7). The authors even state: ‘’the use of an 
external stent which was associated with a high rate of urological complications, should 
be avoided’’. Guleria et al. also reduced their urological complications by changing their 
technique from a non-stented (7.7%) to a double J stented (for a period of 6 weeks) 
ureteroneocystostomy (3.8%)(8). Unfortunately, all these studies have a retrospective 
design and no prospective randomized controlled trials are available. Therefore, in the 
DUET-trial we will investigate whether double J stenting is indeed superior to the use 
of an external stent in reducing the number of urological complications after kidney 
transplantation, as measured by the number of PCN placements.
Methods
Study design
This will be a single-centre randomized controlled trial with a superiority design. Ran-
domization by a computerized system will be performed after intubation in the opera-
tion room, stratified for type of donor (living/ deceased). Physicians participating in this 
study will be unaware of the randomization sequence thereby guaranteeing concealed 
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allocation. Since patients and physicians will notice post-operatively the presence of an 
external stent, the study cannot be blinded. Participants will be included during a period 
of 3 years, 100 recipients each year. Last follow-up moment of all questionnaires will 6 
months after transplantation.
Participants
All adult kidney transplant recipients in the Erasmus University Medical Center (>18yrs) 
are invited to participate.
Exclusion criteria
• Patients who do not understand the Dutch language sufficiently to sign the informed 
consent forms and to fill in the questionnaires
• Patients with a reconstructed urinary tract or conduit after total or partial cystectomy
• Patients with bladder dysfunction that requires continuous or intermittent catheter-
ization
• Donor kidneys with more than one ureter
• Patients with primary FSGS and residual urine production (because FSGS can prog-
ress rapidly in the new kidney graft and using an external stent gives the possibility 
of monitoring the transplants urine on proteinuria, i.e. a first sign of FSGS recurrence)
Withdrawal, dropout, and discontinuation
Subjects can leave the study at any time for any reason if they wish to do so without 
any consequences. The investigator can decide to withdraw a subject from the study for 
urgent medical reasons. These patients will not be replaced, as we have anticipated on 
some missing data in our power calculation.
Intervention
After the vascular anastomosis, the transplant surgeon will perform an extravesical anas-
tomosis as described by Lich-Gregoir (9, 10). A myotomy of 2-3 cm on the anterolateral 
surface of the bladder dome is performed to expose the mucosa of the bladder wall. A 
small incision is made in the mucosa. The transplanted ureter is trimmed and spatulated 
posteriorly. The bladder mucosa is sutured to the ureter with a running absorbable 
suture. The detrusor muscle is closed over the anastomosis by one or two interrupted 
absorbable sutures to create a sub-mucosal tunnel with an antireflux mechanism. Par-
ticipants who are randomized to external stenting will receive an externalised 7 French 
ureteric stent (Teleflex®). Participants who are randomized to double J stenting will 
receive a short (12cm) internal Double J 7 French stent (Teleflex®). The tip of both stents 
will be positioned in the pelvis of the transplanted kidney. The position of the stent will 
be verified during ultrasonography, which is being performed the day after surgery as 
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standard post-operative care. External stents will be removed 9 days post-operatively. 
Double J stents will be removed after 3 weeks by cystoscopy in the outpatient clinic of 
the department of urology. An antibiotic prophylaxis will be used during this procedure 
based on the latest urinary cultures. Recipients will be asked to fill in questionnaires at 
different time points (pre-operative, week 2, week 6 and 6 months after transplantation), 
including a Visual Analogue Score (VAS), quality of life questionnaire (SF-36), Euro-Qol 
(EQ-5D) and ‘Werk en Zorg’ questionnaires.
Outcomes and measures
Our main study endpoint is the number of percutaneous nephrostomy (PCN) drainages. 
The secondary study parameters are the number of urinary tract infections, macroscopic 
haematuria, radiological interventions, surgical re-interventions and stent obstruction 
or dysfunction. Additionally, a quality of life and cost effectiveness analysis will be per-
formed by using questionnaires. Validated questionnaires for pain, quality of life, health 
state, work efforts and disabilities in daily life are measured by the VAS, Euro-Qol, SF-36 
and ‘Werk en Zorg’. Other study parameters are baseline values, which might intervene 
with the main study parameter: donor age and gender, recipient age and gender, body 
mass index, smoking, ASA classification, operation time and return to normal daily 
activities.
Adverse events
The sponsor will suspend the study if there is sufficient ground that continuation of 
the study will jeopardise subject health or safety. The sponsor will notify the accredited 
medical ethical board without undue delay of a temporary halt including the reason 
for such an action. The study will be suspended pending a further positive decision by 
the accredited medical ethical board. The investigator will take care that all subjects are 
kept informed. The sponsor will report serious adverse events (SAEs) to the accredited 
medical ethical board. A data safety monitoring board will be installed to evaluate this 
study after every 50 included patients.
Randomization and blinding
Randomization will be performed after intubation in the operation room by an electronic 
system, stratified for type of donor (living/deceased). Since patients and physicians will 
notice post-operatively the presence of an external stent, the study cannot be blinded.
Date entry and quality control of data
The coordinating investigator collects all data. Every patient is coded into numbers. The 
coordinating and principal investigators have access to the source data. Data will be 
stored for 15 years.
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Sample size calculation
This study aims to show that a double J stent results in fewer PCN placements. Based 
on an two-sided alpha of 0.05, 149 patients are needed to have an 80% power to reject 
the null hypothesis of no effect when tested with Fisher’s exact test when the double J 
stent in fact reduces the probability of PCN placement from 9% to 1.5% (3,5) To allow for 
a few non evaluable cases we randomize 150 patients per arm. (SAS Power and Sample 
Size 14.1)
Statistical analysis
The primary study outcome is PCN placement. This is a categorical variable and will be 
presented as number (percentage). Continuous variables will be presented as median 
(range) en mean with standard deviation, depending whether the variable is normally 
distributed. Categorical variables will be compared with the Chi-square test. Continuous 
variables will be compared with the Mann-Whitney-U test or independent T test. The 
questionnaires, filled out at different time points, will be analysed with a linear mixed 
model. All analyses will be conducted using IBM SPSS Statistics for Windows (version 
20.0. Armonk, NY: IBM Corp, USA). A p-value <0.05 (two-sided) will be considered statisti-
cally significant.
Discussion
In this single center randomized controlled trial, we will investigate whether double J 
stenting is superior to single J (external) stenting in preventing urological complications 
after kidney transplantation.
It has been demonstrated that stent placement can minimize the number of urological 
complications (3, 4). In our center, we have used an external stent for several years and 
urological complications are reported up to 9% of the kidney transplant recipients (5). In 
literature, the double J stent even has less urological complications 0-5.4% and the use 
of a double J is associated with a 2-day reduction of hospital stay (6, 7). Unfortunately, 
all these studies are retrospective and no well-designed prospective randomized con-
trolled trial is available on this matter.
Therefore, we present this study protocol of the DUET-trial. A randomized controlled 
trial, which will be conducted at the Erasmus University Medical Center, Rotterdam, The 
Netherlands.
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Abstract
The objective was to evaluate the incidence and treatment of incisional hernia follow-
ing kidney transplantation, and to identify potential risk factors. A retrospective cohort 
study was performed. All kidney transplant recipients between 2002 and 2012 were 
included. Two groups were identified: patients with incisional hernia and patients with-
out. Risk factor analysis for development of incisional hernia was performed. A total of 
1564 kidney recipients were included. Fifty patients (3.2%) developed incisional hernia. 
On univariate analysis, female gender (54% vs. 35% p = 0.006), BMI>30 kg/m2 (38 % 
vs. 17%, p< 0.001), concurrent abdominal wall hernia (30% vs. 16%, p=0.007), multiple 
explorations of the ipsilateral iliac fossa (38% vs. 19%, p=0.001), left iliac fossa implanta-
tion (36% vs 24%, p=0.046), history of smoking (72% vs 57%, p=0.032) and duration 
of surgery (210 minutes vs. 188 minutes, p=0.020) were associated with the develop-
ment of incisional hernia. In multivariate analyses, female gender (HR 2.6), history of 
smoking (HR 2.2), obesity (BMI >30) (HR 2.9), multiple explorations of the ipsilateral iliac 
fossa (HR 2.0), duration of surgery (HR 1.007), and concurrent abdominal wall hernia (HR 
2.3) were independent risk factors. Twenty-six of 50 patients (52%) underwent surgi-
cal repair, of which nine (35%) required emergency repair. The incidence of incisional 
hernia following kidney transplantation is 3.2%. We found obesity (BMI>30), female 
gender, concurrent abdominal wall hernias, history of smoking, duration of surgery, and 
multiple explorations to be independent risk factors for the development of incisional 
hernia after kidney transplantation. These risk factors should be taken into account to 
prevent incisional hernia.
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Introduction
Incisional hernia is one of the most frequent postoperative complications after ab-
dominal surgery. The incidence varies between 11 and 20% in general population and 
may be even higher in risk subgroups (1-4). Incisional hernia has great impact on the 
health related quality of life and body image (4, 5). Known risk factors for development 
of incisional hernia are obesity, aneurysm of the abdominal aorta, immunosuppressive 
therapy, and postoperative wound infection (1, 4-7). Hence, transplant recipients may 
have an increased risk to develop incisional hernia due to the use of postoperative im-
munosuppressive therapy resulting in impaired wound healing (5, 7).
The incidence of incisional hernia after kidney transplantation in literature, however, is 
reported to be remarkably low and varies between 1% and 7% (6, 8-14).
The use of a mesh is the gold standard for the treatment of incisional hernia. However, 
also with mesh placement, recurrence rates are still very high, up to 32%, and the use 
of mesh facilitates possible mesh related complications such as seroma formation, he-
matoma, mesh infection, and enterocutaneous fistula (2). Additionally, mesh placement 
after kidney transplantations makes the iliac fossa less accessible for future transplant 
removal or kidney retransplantation in the ipsilateral iliac fossa. On the other hand, a 
conservative treatment of incisional hernia leads to secondarily high crossover rates to 
surgical hernia repair with increased postoperative morbidity and mortality, particularly 
in patients who need emergency surgery due to incarceration of the hernia contents 
(15).
We conducted this retrospective case control study to evaluate the incidence and treat-
ment of incisional hernia following kidney transplantation, and to identify independent 
potential risk factors for the development of incisional hernia.
Methods
A retrospective cohort study was performed at the department of Transplant Surgery 
of the Erasmus University Medical Center, Rotterdam, the Netherlands. All patients who 
underwent kidney transplantation between January 2002 and December 2012 were 
identified from the electronic hospital data systems. Electronic hospital data systems and 
medical charts of all kidney transplantations were manually reviewed and patients diag-
nosed with incisional hernia were identified. Second transplantations in the contralateral 
fossa were considered to be new cases; on the other hand, a second transplantation in 
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the ipsilateral fossa was defined as a surgical re-intervention. Our cohort was divided in 
two groups, one group of kidney transplant recipients that developed incisional hernia 
and one who did not develop incisional hernia during follow up. The following patient 
characteristics and clinical data were registered in search for potential risk factors: pa-
tient demographics (i.e. gender, body mass index (BMI), age), preoperative comorbidities 
associated with impaired wound healing or incisional hernia (i.e. diabetes mellitus (DM), 
preoperative immunosuppressive therapy, smoking, pre-emptive transplantation, other 
concurrent hernia), perioperative data (i.e. deceased/living donor, implantation side, 
duration of surgery, surgery during after hours, and multiple explorations of ipsilateral 
fossa) and hernia characteristics (i.e. time to diagnose, treatment, emergency repair, use 
of mesh, recurrence). After hours were defined as surgery starting between 5 p.m. and 
8 a.m. Exploration of the ipsilateral iliac fossa included re-transplantations, transplant 
removal, or complication surgery (i.e. urological complications, bleeding). All patients 
had a semilunaire supra inguinal incision to gain access to retroperitoneal space. Stan-
dard immunosuppressive therapy consisted of tacrolimus, mycophenolate mofetil, and 
prednisolone. Prednisone was gradually tapered and eventually stopped at 4 months. 
On indication, conversions to ciclosporin, azathioprine, sirolimus or prednisone have 
been performed in individual patients. Incisional hernias were diagnosed at the outpa-
tient clinic or emergency department. The follow-up of kidney transplant recipients is 
done by the nephrologists in our center. In case the nephrologist assumed an incisional 
hernia, the patient was referred to the surgical outpatient clinic. Incisional hernias were 
generally diagnosed by physical examination by surgeons. When there was doubt after 
physical examination additional radiologic imaging was performed. In case of incisional 
hernia repair, defects were corrected either primary or with mesh in intraperitoneal, 
preperitoneal, sublay or onlay fashion. If possible a tension free, non-bridging technique 
was preferred over a bridging technique to close the defect.
Data analysis
SPSS 21.0 (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, version 21.0. 
Armonk, NY: IBM Corp.) was used for all statistical analyses. Continuous variables were 
presented as means with Standard Deviations (SD) or as medians with Inter Quartile 
Range (IQR). Categorical variables were presented as numbers with percentages (%). 
Independent T-test, Mann-Whitney U and Chi-square tests were used to compare risk 
factors for incisional hernia after kidney transplantation. Univariate regression analyses 
were performed for development of incisional hernia with risk factors by analysing each 
potential risk factor separately. Potential risk factors that were significantly related to 
incisional hernia in the univariate regression analysis (i.e. BMI >30 kg/m2, gender, con-
current abdominal wall hernia, history of smoking, multiple explorations of the ipsilat-
eral fossa, duration of surgery, and implantation side) were included in our multivariate 
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regression analyses. The multivariate regression analyses were performed using a Cox 
Proportional Hazards (CPH) model to control for effects of multiple potential risk factors. 
A p-value less than 0.05 was considered statistically significant.
Results
Baseline characteristics demography table 
Between 2002 and 2012 1564 kidney transplantations were performed; 1004 (64%) were 
male recipients, mean age at transplantation was 51 years (SD 14.4 years). Mean BMI was 
25.7 (SD 4.7). Median follow up was 59 months (IQR 34-95 months), 274 (17.5%) patients 
died during follow up. Preoperatively, 349 (23%) patients reported to be current smok-
ers at time of transplantation, 532 (35%) had a smoked in the past and 659 (42%) never 
smoked. One thousand and twenty-two (65%) transplantations concerned kidneys of a 
living donor, 542 (35%) grafts were from deceased donors. Prior to transplantation 370 
(24%) patients did not receive hemo- or peritoneal dialysis. Preoperatively, in total 222 
(14%) patients already used immunosuppressive drugs of whom 3 patients (6%) devel-
oped incisional hernia and 219 patients (15%) did not, (p=0.089). 1187 (76%) kidneys 
were placed in the right and 377 (24%) in the left iliac fossa. Mean duration of surgery 
was 188 minutes (SD 44 minutes) and 294 (19%) transplantations took place during 
after-hours (between 5:00 p.m. and 7:59 a.m.). Three hundred and one (19%) patients 
needed surgery in the same fossa after initial transplantation due to bleeding, urological 
complications or transplant removal.
Incisional hernia
A total of 50 (3.2%) patients developed incisional hernia. Median time between trans-
plantation and the development of incisional hernia was 68 weeks (IQR 24-149 weeks). 
The time to develop incisional hernia after kidney transplantation is presented in Figure 
1. The cumulative incidence of development of incisional hernia was 1.6% at 12 months 
after transplantation, 3.7% at 60 months and 4.4% at 120 months postoperative. Poten-
tial risk factors for incisional hernia, after univariate analyses are presented in Table 1. 
Surgical repair of the incisional hernia was performed in 26 patients (52%), 24 (48 %) 
were treated conservatively. Surgical repair was performed with polypropylene mesh 
in 15 patients, 4 polyester meshes were placed, 1 Vicryl® mesh was placed because of 
a contaminated environment, and 6 patients underwent hernia repair without mesh 
(5 patients without mesh placement were operated during an emergency repair). The 
mesh was placed with bridging technique in 11 patients and in 7 patients non-bridging 
techniques was used, in 2 patients the details of the technique were not documented. 
Nine patients (35%) required emergency repair due to small bowel incarceration. In 6 
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of 26 (23%) patients recurrence of incisional hernia occurred. Two patients with a recur-
rence were initially corrected with polyester mesh, 2 with polypropylene mesh, 1 with 
Vicryl ® mesh, and 1 defect was closed primarily.
Risk factor analyses
Univariate regression analysis showed that concurrent abdominal wall hernia (HR 2.4; 
p=0. 005), female gender (HR 2.1; p=0.011), history of smoking (HR 1.9; p=0.035), obesity 
(HR 3.0; p<0.001), multiple explorations in the ipsilateral fossa (HR 2.7; p=0.001), duration 
of surgery (HR 1.009; p<0.001), left sided implantation (HR 1.8 p=0.046) were associated 
with the development of incisional hernia. When we corrected for possible confounding 
variables in the multivariate regression analysis, all aforementioned risk factors except 
for the implantation side remained independent risk factors for the development of 
incisional hernia after transplantation. Hazard ratios with 95% confi dence intervals are 
presented in Table 2.
Figure 1. Development of incisional hernia following kidney transplantation
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Discussion
In this retrospective analysis, we found an incidence of incisional hernia after kidney 
transplantation of 3.2%. Presumably this incidence is lower compared to other abdomi-
nal wall incisions due to the anatomical location of the iliac incision in kidney transplan-
tation and the transfascial and muscular approach perpendicular to the tension lines 
of the abdomen. The outcome corresponds with the incidence described in literature 
Table 1. Univariate analyses
With IH (n=50) Without IH (n=1514) P-value
Female gender (%) 27 (54) 533 (35) 0.006
BMI, kg/m2 (mean) (SD) 28.7 (5.6) 25.6 (4.6) <0.001
BMI > 30 kg/m2 (%) 19 (38) 260 (17) <0.001
Age (mean) (SD) 51.4 (12.1) 51.4 (14.5) 0.968
Diabetes mellitus (%) 12 (24) 300 (20) 0.466
Pre-emptive transplantation (%) 16 (32) 354 (23) 0.158
Pre-operative immunosuppression 3 (6) 219 (15) 0.089
Current smoking (%) 11 (22) 338 (23) 0.909
History of smoking* (%) 36 (72) 845 (57) 0.032
Concurrent abdominal wall hernia (%) 15 (30) 238 (16) 0.007
Living donor (%) 31 (62) 991 (66) 0.613
Left side implantation (%) 18 (36) 359 (24) 0.046
Duration surgery, min (mean) (SD) 210 (64) 188 (43) 0.020
Surgery during after-hours (%) 12 (24) 282 (19) 0.340
Multiple explorations same fossa (%) 19 (38) 282 (19) 0.001
*History of smoking includes all current and past smokers 
P-values are 2-sided. For dichotomous variables chi-square test and for continuous variables Mann-Whitney 
U or t-test was performed.
IH, Incisional hernia; BMI, body mass index; 
Table 2. Multivariable risk factor analyses
HR 95% CI P-value
BMI >30 kg/m2 2.9 1.6-5.2 <0.001
Female gender 2.6 1.4-4.7 0.002
Concurrent abdominal wall hernia 2.3 1.2-4.3 0.009
History of smoking 2.2 1.1-4.1 0.019
Multiple explorations 2.0 1.1-3.7 0.026
Left sided implantation 1.6 0.9-2.8 0.132
Duration of surgery, min 1.007 1.001-1.012 0.014
2-sided chi-square tests were performed
HR, hazard ratio; CI, confidence interval; BMI, body mass index.
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(6, 12-14). Beside the known risk factors smoking and obesity, we found female gender, 
duration of surgery, other abdominal wall hernia, and multiple exploration of the ipsilat-
eral iliac fossa to be new independent risk factors for development of incisional hernia 
after kidney transplantation. Surgical repair of the incisional hernia was performed in 26 
(52%) patients; nine (35%) required emergency repair.
This study describes new independent risk factors for the development of incisional 
hernia after transplantation and gives information about the treatment of incisional 
hernia in a well-defined surgical population. A recent publication provided an overview 
of incisional hernia formation following abdominal organ transplantation, including 
2247 kidney transplantations. The authors reported an incidence of 7% after 10 years 
follow up. The only independent risk factors for development of incisional hernia in their 
cohort were the non-use of mycophenolate mofetil and surgical site infection (6). In 
this study, we identified predisposing independent risk factors, such as female gender, 
duration of surgery, obesity, other abdominal wall hernia, multiple explorations, and 
smoking. These preoperative and perioperative risk factors should be taken into account 
by surgeons when closing the fascia.
According to the guidelines of the European Hernia Society on abdominal wall closure, 
small bite sutures are suggested for fascia closure after midline incisions in order to 
prevent incisional hernia. In the small bite technique the laparotomy wound is closed 
with a single layer suturing technique taking bites of fascia of 5–8 mm and placing 
stitches every 5 mm (16, 17). Furthermore, a running suture length to wound length 
ratio of at least 4 to 1 is advised (16, 18). Although this technique in advised for midline 
incisions, it can also be considered during iliac fossa closure in high-risk transplant 
recipients. However, more research is necessary to prove the effect of small bite sutures 
in iliac fossa incisions. Prophylactic mesh placement in kidney transplant recipients with 
non-modifiable pre-operative risk factors is not preferrable, as this would make future 
explorations of the iliac fossa more difficult. Moreover, the use of immunosuppressive 
drugs postoperatively could make meshes more prone for mesh infection.
Preoperative weight reduction in obese patients should not only be advised to benefit 
graft survival, prevent diabetes and reduce hospital stay, but also to prevent postopera-
tive complications such as wound infection and incisional hernia (19).
Another publication reported an incidence of 2.6% for incisional hernia after kidney 
transplantation of which 71% needed surgical repair. These authors reported a recur-
rence rate of 20%. This corresponds with our recurrence rate of 23% and recurrence rates 
after other abdominal incisional hernia (2, 13).
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Synthetic polypropylene was the mesh most frequently used in our cohort, which is 
also being mentioned in literature for surgical repair of incisional hernia after kidney 
transplantation (10-14). Nevertheless, it is conceivable that biological prosthesis (i.e. 
porcine dermis collagen) could be useful in patients who are prone to develop wound 
infection. Biological meshes are already deemed feasible and safe, however, the number 
of patients treated with these meshes is still limited and the advantage over synthetic 
meshes is not yet properly investigated (20).
The prolonged duration of the transplantation procedure in the group that developed 
incisional hernia can be explained by the complexity of the procedure. Also, the relation-
ship between obesity and prolonged duration of surgery has previously been described 
(19).
The present study has few limitations most of them attributable to the retrospective 
design. A few potential risk factors, for instance number of wound infections, which are 
known to be a potential risk factor for the development of incisional hernia, could not be 
analyzed thoroughly in our hospital data systems (6, 21). Because the diagnosis of inci-
sional hernia is made clinically and radiography is not a standard procedure, the number 
of incisional hernias could be underestimated. However, patients had meticulous fol-
low up with physical examination postoperatively in our outpatient clinic. Moreover, 
patients who developed incisional hernia who present in another hospital are always 
referred to the surgical department in our center.
In conclusion, we found that the incidence of incisional hernia following kidney trans-
plantation is 3.2%. The emergency surgical repair rate of the incisional hernia was 35% 
and recurrences occurred in 23%. Beside the known risk factor obesity (BMI>30) and 
smoking, we found female gender, concurrent abdominal wall hernias, duration of 
surgery, and multiple explorations appear to be new independent risk factors for the de-
velopment of incisional hernia after kidney transplantation. Surgeons should be aware 
of these risk factors when closing the fascia after transplantation or re-exploration in 
order to prevent incisional hernia.
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Abstract
The aim of this study is to review the surgical outcome of kidney retransplantation in 
the ipsilateral iliac fossa in comparison to first kidney transplants. The database was 
screened for retransplantations between 1995-2013. Each study patient was matched 
with 3 patients with a first kidney transplantation. Just for graft and patient survival 
analyses we added an extra control group including all patients receiving a second 
transplantation in the contralateral iliac fossa. We identified 99 patients that received 
a retransplantation in the ipsilateral iliac fossa. There was significantly more blood loss 
and longer operative time in the retransplantation group. The rate of vascular complica-
tions and graft nephrectomies within 1 year was significantly higher in the study group. 
The graft survival rates at 1 year and 3, 5 and 10 years were 76%, 67%, 61% and 47% 
in the study group vs. 94%, 88%, 77% and 67% (P<0.001) in the first control group vs. 
91%, 86%, 78% and 57% (P=0.008) in the second control group. Patient survival did not 
differ significantly between the groups. Kidney retransplantation in ipsilateral iliac fossa 
is surgically challenging and associated with more vascular complications and graft loss 
within the first year after transplantation. Whenever feasible, the second renal transplant 
(first retransplant) should be performed contralateral to the prior failed one.
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Introduction
Kidney transplantation is the treatment of choice for end stage renal disease (ESRD). It 
offers a better quality of life and longer survival compared to remaining on dialysis (1). In 
2013, 25% of patients on the Dutch kidney transplant waiting list awaited a retransplant. 
The population enlisted for a retransplant differs from the population enlisted for the 
first time. Reasons for loss of the first kidney graft may also threaten following grafts. 
The most important factor probably is rejection. Both acute and chronic allograft rejec-
tion may result in immunization and increased chances for rejection of the following 
graft. Panel reactive antibody (PRA) best describes the degree of immunization and in 
multivariable analysis high levels are associated with graft failure censored for death. 
In multivariable analysis, the number of preceding renal transplants does not influence 
graft survival when PRA is present in the model (2).
Other reasons for first (and following) graft loss may be recurrence of original disease 
e.g. various types of glomerulonephritis (e.g FSGS, IgA nephropathy), systemic diseases 
and diabetes mellitus. Thrombosis of renal vein or artery after transplantation is an in-
frequent cause of graft loss and always leads to analysis of clotting disorders to prevent 
recurrence. Furthermore, retransplants also present a surgical challenge due to possible 
adhesions, difficulties reaching the iliac vasculature or earlier manipulation of the blad-
der to establish the ureterovescial anastomosis.
Several retransplantation techniques have been described including the transperi-
toneal, retroperitoneal and orthotopic approach (3-6). This raises the question which 
technique should be preferred. As in most centers, in first instance we implant the renal 
graft in the extraperitoneal iliac fossa. If a retransplantation must be performed, the use 
of the contralateral iliac fossa is advocated. However, in case of a third or even fourth 
retransplant, it is unavoidable to explore an iliac fossa that has already been dissected 
for the previous implantation and for removal of the non-functioning graft.
So far, only a limited number of studies have been published on the use of the ipsilateral 
iliac fossa for retransplantation and they included a low number of patients or patients 
undergoing simultaneous pancreas-kidney transplantation (7-9). This finding may be 
due to the exceptional indication for a third of fourth retransplant in the past. In this 
manuscript, we present a retrospective case-controlled study on the surgical challenges 
of kidney retransplantation in the ipsilateral iliac fossa including the largest number of 
patients reported to date.
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Methods
Study population and data selection
The database of the Erasmus MC, University Medical Center, Rotterdam, includes a total 
of 2307 adult kidney transplants performed between January 1995 and December 2013. 
The database was screened for patients who received a retransplant in the ipsilateral 
iliac fossa. Pediatric patients were excluded.
We conducted a case-controlled study matching three control patients to each study 
patient. The criteria for the matching process were recipient gender and age, year of 
transplantation and type of donor (deceased vs. living). All control patients received a 
first kidney transplant. Patients with simultaneous liver and/or pancreas transplantation 
were excluded. Data on the surgical procedure, hospital stay as well as follow up data 
were analyzed. Baseline characteristics included recipient gender and age, implanta-
tion side, body mass index, number of transplants with a positive crossmatch, number 
of ABO-incompatible transplants, type of donor (deceased vs. living), left/right donor 
kidney, number of prior transplants, cold and warm ischemia time, number of arteries 
of the transplanted kidney, anti-thymocyte globulin (ATG) therapy and follow up in 
months. The immunologic risk was defined by current panel reactive antibodies (PRA), 
highest PRA and human leukocyte antigen (HLA) mismatches. Outcome parameters as 
operative time, estimated blood loss, urological complications (defined as percutaneous 
nephrostomy placement (PCN)), vascular complications and surgical re-interventions 
were analyzed. Surgical re-interventions were defined as all procedures performed 
within one year after kidney transplantation. Removal of a continuous ambulant perito-
neal dialysis (CAPD) catheter was not included as re-intervention. Re-interventions were 
divided into 4 categories: 1) Surgical re-interventions due to post-operative bleeding; 
2) Graft nephrectomy; 3) Surgery due to complications at the site of the ureterovesical 
anastomosis; 4) Other surgical re-interventions (abdominal, hemodialysis shunt, vascu-
lar, etc.). The glomerular filtration rate (GFR) was calculated at 3 and 12 months post 
transplantation using the Cockroft-Gault formula. Date of graft failure was defined as 
the first day that hemodialysis or peritoneal dialysis was resumed. Graft survival was 
defined as the number of months between date of kidney transplantation and date of 
graft failure or end of observation period. Graft survival was censored for death.
Just for graft and patient survival analyses, we added an extra control group including 
all patients receiving a second transplant in the contralateral iliac fossa between 1995-
2013. Second transplants in the contralateral iliac fossa share a higher immunological 
risk, but lack the surgical difficulties of a fossa that has been explored earlier because 
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of a former transplantation with or without graft nephrectomy. Follow-up was until July 
2014 for all cases and controls.
Surgical technique
All recipients were preoperatively screened by a nephrologist, a transplant surgeon 
and an anesthesiologist. Pre-operative screening by a cardiologist, urologist or other 
specialist was performed only when indicated by previous history or special findings at 
screening. The extraperitoneal approach of the iliac fossa was performed in all patients. 
Firstly, the renal vein was anastomosed to external iliac vein. In retransplant patients, the 
venous anastomosis could also be connected to the common iliac vein or the inferior 
vena cava. The renal artery was then anastomosed to the external iliac artery. If this 
artery was not suitable for a recurrent vascular anastomosis, the common iliac artery 
was used. All vascular anastomoses were performed in an end-to-side fashion. We did 
not use the epigastric vessels for the vascular anastomoses. Two types of anastomoses 
between donor ureter and recipient bladder have been performed in the period that 
we studied: an intravesical anastomosis according to a modified Politano-Leadbetter 
(10) or an extravesical anastomosis as described by Lich-Gregoir (11, 12). Until 2003, a 
ureterovesical stent was not part of our standard procedure. Between 2003 and 2010 
all patients with residual urine production of the native kidneys or from a formerly 
transplanted kidney received a stent in the ureterovesicostomy. After 2010, the use of 
an 8-French stent was defined as standard care.
Immunosuppressive treatment
Standard immunosuppressive therapy consisted of tacrolimus, mycophenolate mofetil, 
and prednisolone. However, this changed over the years. In the first period immunosup-
pression consisted of ciclosporin and prednisone. Ciclosporin was dosed on 12-hour 
through levels, while prednisone was started on the day of transplantation and was 
gradually tapered until a maintenance dose of 10 mg per day was reached at 4 months 
after transplantation. In 1996, mycophenolate mofetyl was introduced in our center, 
and was combined with ciclosporin and prednisone. In 1999, tacrolimus was gradually 
introduced and eventually replaced ciclosporin as standard calcineurin inhibitor treat-
ment. It was added to the combination of mycophenolate mofetyl and prednisone. 
Triple therapy was given until 4 months after transplantation: prednisone was gradually 
tapered and eventually stopped at 4 months. This protocol has been used as standard 
immunosuppressive medication since then. On indication, conversions to ciclosporin, 
azathioprine, sirolimus or prednisone have been performed in individual patients.
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Statistical analysis
Categorical variables were presented as numbers (percentage). Continuous variables 
were presented as median (range) if not normally distributed; continuous variables 
with normal distribution were presented as means with standard deviation. Categorical 
variables were analysed using the Chi-square test. Continuous variables were analysed 
using the Mann-Whitney-U test or an independent T-test. All analyses were conducted 
using IBM SPSS Statistics for Windows (version 21.0. Armonk, NY: IBM Corp, USA). A 
p-value <0.05 (two-sided) was considered statistically significant. Graft and patient 
survival were presented using the Kaplan Meier method and compared with a Log rank 
test and Cox regression analyses.
Results
Baseline characteristics
From a total of 2307 kidney transplants conducted in our center between 1995 and 2013, 
we identified 99 (4%) patients that received a retransplant in the ipsilateral iliac fossa. 
Patients were counted multiple times if they had multiple transplants in non-virgin 
sites. Five patients received a second transplant in the ipsilateral iliac fossa due to an 
inaccessible contralateral iliac fossa. Seventy patients received a third kidney transplant, 
eighteen a fourth, five patients a fifth and one patient a sixth transplant. We selected 
297 control patients matching on recipient gender and age, year of transplantation, 
and type of donor (deceased vs. living). In table 1 baseline characteristics of the study 
and control group are compared. As expected, recipient gender, age and type of donor 
were similar in both groups. There were no significant differences in the total number of 
arteries, HLA mismatches, warm and cold ischemia time, recipient BMI, left/right donor 
kidney, and median follow up between both groups. The study group had a significantly 
higher current and historic PRA (P<0.001). In the study group, there were 2 positive 
crossmatch transplants and 2 ABO-incompatible transplants. In the control group, 5 
ABO-incompatible transplants were performed and no transplants across a positive 
crossmatch. ATG induction therapy was used in 11 (11%) recipients of the study group 
and in 25 (8%) of first transplants (P=0.419).
Surgical outcome
In 6 study patients graft nephrectomy of the failed kidney was performed during the 
same session as retransplantation. In 93 patients the failed transplants in the ipsilat-
eral fossa were removed in an earlier session prior to retransplantation. For the venous 
anastomoses the external iliac vein was used in 87 patients and the common iliac vein 
in 7 patients of the study group. In 1 patient the renal vein was anastomosed to the 
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inferior vena cava and in 2 study patients the veins of the previously failed grafts were 
used (of whom one patient returned on dialysis again 35 months after transplantation 
and the other died with a functioning graft 71 months after transplantation). In the 88 
patients of the study group, the renal artery was anastomosed to the external iliac artery 
and in 5 patients to the common iliac artery. In 2 patients the arterial anastomosis was 
made using a vascular prosthesis. One of these patients had primary non-function and 
the other had a partial renal venous thrombosis thus thrombectomy was performed 1 
day after transplantation, hereafter graft function restored and the patient returned to 
Table 1. Baseline characteristics
Characteristics Cases (n= 99) Control (n=297) P-value
Recipient age in years mean ± SD 43 ± 13 45 ± 12 0.342
Recipient gender
Male, n (%) 55 (56%) 165 (56%) 1.00 
Female, n (%) 44 (44%) 132 (44%)  
Type of donor
Deceased, n (%); 63 (64%) 189 (64%) 1.00 
Living, n (%) 36 (36%) 108 (36%)  
Implantation side
Left, n (%) 45 (46%) 73 (25%) <0.001 
Right, n (%) 53 (54%) 223 (75%)  
Donor kidney
Left, n (%) 48 (53%) 130 (47%) 0.278 
Right, n (%) 42 (47%) 148 (53%)  
ABO-incompatible, n (%) 2 (2%) 5 (1.7%) 0.826
Positive Crossmatch, n (%) 2 (2%) 0 0.014
HLA Mismatches median (range) 2.0 (0.0-6.0) 3.0 (0.0-6.0) 0.164
Current PRA in % mean ± SD 32 ± 33 7 ± 20 <0.001
Highest PRA in % mean ± SD 69 ± 31 15 ± 26 <0.001
Number of transplants median (range) 3 (2-6) 1 <0.001
ATG, n (%) 11 (11%) 25 (8%) 0.419
Recipients BMI median (range) 24 (17-38) 24 (15- 42) 0.065
Number arteries median (range) 1 (1-3) 1 (1-5) 0.712
Warm ischemia time in minutes median (range) 29 (11-72) 29 (13-323) 0.591
Cold ischemia time in minutes median (range) 960 (70-2040) 903 (90-2015) 0.096
Ureteroneocystostomy
Intravesical, n (%) 47 (62%) 199 (73%) 0.055 
Extravesical, n (%) 29 (38%) 73 (27%)  
Follow up in months median (range) 60 (0-229) 58 (0-229) 0.671
SD, standard deviation; HLA, human leukocyte antigen; PRA, panel reactive antibodies; ATG, anti-thymo-
cyte globulin; BMI, body mass index
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dialysis 28 months later due to chronic allograft nephropathy. In 2 patients the artery of 
the previously failed graft was used for arterial anastomosis. Both patients had a surgical 
re-intervention due to haemorrhage within 4 days, one graft is still functioning and the 
other failed after 35 months due chronic allograft nephropathy.
Forty-five (46%) retransplant grafts were implanted in the left iliac fossa and 53 (54%) 
in the right iliac fossa. In the control group 223 (75%) grafts were implanted in the 
right and 73 (25%) in the left iliac fossa. Significantly more grafts were implanted in 
the right iliac fossa in the control group (P<0.001). The intravesical technique for the 
ureteroneocystostomy was used in 47 (62%) study patients and in 199 first transplants 
(73%)(P=0.055).
Mean operative time was significantly higher in our study group (241 ± 69 minutes) 
compared to the control group (180 ± 38 minutes; P<0.001). The median estimated blood 
loss per-operatively was higher in the study group compared to the matched controls, 
500ml (range, 0-2565) vs. 300ml (range, 0-3600) respectively (P<0.001). The number of 
hospitalization days was not significantly different between both groups (Table 2).
The incidence of urological complications, measured by placement of percutaneous 
nephrostomy catheters, did not differ significantly. However, the rate of vascular compli-
cations was higher in the study group: 8 patients (8%) vs. 6 patients in the control group 
(2%) (P=0.003). In the study group these were all due to thrombotic events whereas in 
the control group 4 were related to a thrombotic event and 2 to a venous laceration 
(Table 2).
Table 2. Surgical short- and long-term outcome
Characteristics Cases (n=99) Controls (n=297) P-value
Operative time in minutes mean ± SD 241 ± 69 180 ± 38 <0.001
Blood loss in ml median (range) 500 (0-2565) 300 (0-3600) <0.001
Hospital admitted days median (range) 15 (2-73) 14 (4-189) 0.118
PCN placement n (%) 14 (14%) 54 (18%) 0.376
Vascular complications n (%) 8 (8%) 6 (2%) 0.003
-  Thrombotic event 8  4   
- Venous laceration 0 2   
GFR at 3 months median (range) 54 (9-116) 61 (8-144) 0.003
GFR at 12 months median (range) 54 (8-115) 62 (4-138) 0.028
SD, standard deviation; PCN, percutaneous nephrostomy
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Surgical re-interventions within the first year after transplantation were indicated 
because of bleeding, urological complications, and other surgery, but did not differ 
between the study and the control group, as shown in Table 3. However, the rate of 
graft nephrectomies was significantly higher in our study group; 16 nephrectomies in 
the study group (16%) versus 14 nephrectomies (5%) in the matched control group 
(P<0.001). In the study group graft nephrectomy was due to cellular rejection in 5 cases 
(of whom 3 received ATG), circulatory problems in 7 cases (5 thrombotic events, 1 hypo-
volemic shock due to bleeding, and 1 case due to mechanic compression of the graft in 
the fossa). One graft nephrectomy in the study group was due to an infection, 1 due to 
calcium oxalate depositions in the kidney, 1 due to both humoral, and cellular rejection 
combined with thrombosis, and 1 due to recurrence of hemolytic uremic syndrome. In 
the control group graft nephrectomy was performed because of cellular rejection in 6 
cases (of whom 2 received ATG), humoral rejection in 2, and circulatory problems in 5 
(3 thrombotic events and 2 venous lacerations). One graft nephrectomy was indicated 
because of infarction of both the lower and upper pole of the kidney followed by ne-
crosis, abscess formation, and cellular rejection due to cessation of immunosuppression 
(Table 3).
One patient in the study group with a failed retransplant, who was scheduled to receive 
another retransplant in the ipsilateral fossa, was found not to be transplantable because 
of severe fibrosis of the iliac fossa per-operatively.
Table 3. Surgical re-intervention within 1 year
Cause Cases (n=99) Controls (n=297) P-value
Bleeding n (%) 10 (10%) 14 (5%) 0.052
Graft nephrectomy n (%) 16 (16%) 14 (5%) <0.001
- Cellular rejection 5 6  
- Humoral rejection 0 2  
- Circulation 7 5  
- Other 4 1  
Urological complications n (%) 6 (6%) 25 (8%) 0.450
Other surgical interventions n (%) 16 (16%) 33 (11%) 0.136
- Abdominal 4  15   
- Shunt related 4  8   
- Vascular 1  1   
- Rest 7  9   
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Long-term survival
The GFR was significantly lower in the study group compared to the control group at 3 
and 12 months post transplantation (Table 2). The graft survival rates at 1 year and 3, 5 
and 10 years were 76%, 67%, 61% and 47% in the study group vs. 94%, 88%, 77% and 
67% in the control group. Table 4.
Just for survival analyses we added an extra control group of all 270 patients receiving a 
second kidney transplant in the contralateral iliac fossa between 1995-2013. This group 
had graft survival rates at 1 year and 3, 5 and 10 years of respectively 91%, 86%, 78% 
and 57%. Table 4. This group contained 164 males (61%) and 106 females (39%) of which 
140 (52%) deceased donors and 130 (48%) living donors. Median number of HLA mis-
matches of the additional control group was 3.0 (0.0-6.0). This was significantly higher 
compared to the study group with a median of 2.0 (0.0-6.0; P=0.001) and control group 
of first transplants with a median of 3.0 (0.0-6.0; P=0.026). Mean current PRA of the ad-
ditional control group was 16 ± 23%. This was significantly lower than the study group 
(32 ± 33%; P<0.001) and significantly higher than the control group of first transplants 
(7 ± 20%; P<0.001). The mean highest PRA of the additional control group was 40 ± 32%. 
This was significantly lower than the study group (69 ± 31%; P<0.001) and significantly 
higher than the control group of first transplants (15 ± 26%; P<0.001).
Table 4. One year and 3-, 5- and 10-years graft survival
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Control 1: First transplants (n=297) 94% 88% 77% 67% 1.00* - 0.83** 0.257
Control 2: Second transplants contralateral (n= 270) 91% 86% 78% 57% 1.21* 0.257 1.00** - 
Study group overall (n= 99) 76% 67% 61% 47% 1.99* <0.001 1.66** 0.009 
-  Second transplants ipsilateral (n=5) 60% 60% 60% 60% 2.98* 0.128 2.47** 0.207 
- Third transplants (n= 70) 74% 63% 58% 45% 2.22* <0.001 1.84** 0.005 
- Fourth transplants (n=18) 89% 83% 76% 53% 1.25* 0.602 1.04** 0.934 
- Fifth transplants (n=5) 80% 80% 60% 60% 1.38* 0.651 1.15** 0.848 
- Sixth transplants (n=1) 0% 0% 0% 0% 16.12* 0.006 13.37** 0.011 
HR, hazard ratio:
* hazard ratio with the first control group as indicator 
** hazard ratio with the second control group as indicator
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Table 4 shows the graft survival rates specified for each number of retransplants. The 
patient that received a sixth transplant had a thrombosis of the renal vessels the day 
after transplantation and graft nephrectomy was performed. Cox regression analyses 
were performed using both the first and second control group as indicator. Third and 
sixth transplants had a significantly higher risk for graft failure. Table 5 shows patient 
survival rates specified for each number of retransplants. There were no significant dif-
ferences in patient survival between the groups.
Figure 1 shows the Kaplan-Meier graft survival curve of the study and both control 
groups. Most graft failures in the study group were within the first month after trans-
plantation. After one year, graft survival curves were almost parallel. Log rank test of 
graft survival between the study and the first control group was P<0.001, between the 
study and the second control group it was P=0.008 and between the both control groups 
it was P=0.237. Figure 2 provides more insight in the patient survival of the study and 
both control groups. There were no significant differences in patient survival between 
the three groups.
Discussion
Renal retransplantation in the ipsilateral iliac fossa is surgically challenging. In this case-
controlled study we showed that operative time and intra-operative estimated blood 
Table 5. One year and 3-, 5-, 10- years patient survival
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Control 1: First transplants (n=297) 96% 91% 85% 71% 1.00* - 1.17** 0.412
Control 2: Second transplants contralateral (n= 270) 95% 92% 87% 77% 0.85* 0.412 1.00** - 
Study group overall (n=99) 92% 86% 83% 64% 1.17* 0.513 1.37** 0.204 
- Second transplants ipsilateral (n=5) 80% 80% 80% 40% 2.63* 0.181 3.07** 0.121 
- Third transplants (n= 70) 90% 85% 79% 61% 1.31* 0.322 1.53** 0.123 
- Fourth transplants (n=18) 94% 89% 89% 67% 0.89* 0.814 1.04** 0.945 
- Fifth transplants (n=5) 100% 100% 100% 100% 0.00* 0.961 0.00** 0.962 
- Sixth transplants (n=1) 100% 100% 100% - 0.00* 0.986 0.00** 0.986 
HR, hazard ratio:
* hazard ratio with the first control group as indicator 
** hazard ratio with the second control group as indicator
114 CHAPTER 9
loss are signifi cantly higher in patients that received a retransplant in the ipsilateral 
iliac fossa. Furthermore, patients with a retransplant have a signifi cantly higher risk for 
thrombotic events of the renal vessels. The number of surgical re-interventions to solve 
urological complications, post-operative bleeding or other causes were comparable 
in both groups. However, the rate of graft nephrectomies performed in the fi rst year 
after transplantation was signifi cantly higher in the study group then in the fi rst control 
group, with 16% vs 5%, respectively. The main reasons for graft nephrectomy within the 
study group were a thrombotic event in the renal vessels or cellular rejection. The overall 
graft survival was lower in the study group vs. both control groups, however patient 
survival was not aff ected by the number of transplantations.
There are a number of studies reporting on the use of the ipsilateral fossa in case of a 
retransplantation. Mazzucchi et al. included 21 third and following retransplants. Mean 
operative time was 327 minutes for retransplants and 212 minutes for fi rst transplants. 
Surgical complications occurred in 4 patients, including two arterial thrombosis and 
two ureteral obstructions. One year graft survival was 57% for retransplants vs. 86% 
Figure 1. Kaplan- Meier graft survival curve
Annotation: Log rank test between the study and fi rst control group (P<0.001). Log rank test between the 
study and the second control group (P=0.008). Log rank test between both control groups (P=0.237).
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for fi rst transplants (7). Another study analyzed 30 patients who received their third 
transplant. Six out of 30 grafts were lost, 3 due to acute rejection, 2 due to chronic 
allograft nephropathy and 1 due to venous thrombosis. They reported 26.6% surgical 
complications. Graft survival at 1, 5 and 10 years were 87%, 76% and 57%, respectively 
(13). Kienzl- Wagner et al. analyzed 56 third and fourth kidney transplants. Third kidney 
graft survival rates at 1-5 year(s) were 73%- 54%. Surgical complications occurred in 21 
patients including 4 patients with a wound dehiscence, 4 hydronephrosis, 4 hematomas, 
2 lymfoceles, 2 perforations of the bowel, 1 rupture of the anastomosis, and 1 torsion of 
the kidney graft. Two grafts were lost due to the bowel perforation (14). LaMattina et 
al. have analyzed long-term graft survival for renal retranplants in prior simultaneous 
pancreas-kidney recipients. They found that most graft losses were not due to technical 
complications, but to immunological causes or patients who died with a functioning 
graft. However, they only included patients who received two transplants in the same 
iliac fossa compared to our study group where multiple explorations of the ipsilateral 
iliac fossa were performed including the transplantations and the removal of the pre-
viously failed grafts (8). Multiple explorations of the iliac fossa could result in more 
technical diffi  culties due to adhesions. Alternative surgical approaches for retransplants 
are described in literature. Chedid et al. have used renal vessel of the failed allograft 
Figure 2. Kaplan- Meier patient survival curve 
Annotation: Log rank test between the study and the fi rst control group (P=0.501). Log rank test between 
the study and the second control group (P=0.203). Log rank test between both control groups (P= 0.404).
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successfully in six retransplants with severe aortailiac atherosclerosis and fibrosis on the 
iliac vessels. There was one postoperative complication of diminished arterial inflow, 
that was corrected during a surgical re-intervention (9).
Although retransplantation is accompanied by more frequent complications and shorter 
graft survival, the results are superior to life time dialysis. The quality of life and patient 
survival are higher by avoiding lifelong dialysis and its societal cost-effectiveness is 
estimated to save $9,656 per quality- adjusted life-year (1, 15, 16).
There are some limitations to this study. First, the immunosuppressive regime between 
1995 and 2013 has changed, which may have biased our results. We tried to resolve 
this point by matching the control group in the same year of transplantation. We tried 
to bypass the immunological challenges of retransplants by adding an additional 
control group of all 270 patients who received a second transplant in the contralateral 
iliac fossa between 1995-2013. This additional control group of only second transplants 
provides more insight in graft survival with a higher immunological risk however lacks 
the surgical difficulties of a fossa that has been explored earlier. The graft survival rates 
of the control group and the additional control group were respectively 94%, 88%, 77% 
and 67% vs. 91%, 86%, 78% and 57%, P=0.237. This emphasizes the surgical challenges 
of retransplants in an earlier explored iliac fossa with graft survival rates of 76%, 67%, 
61%, and 47%, respectively. Due to the retrospective design, a few important variables, 
such as the number of urinary tract infections and surgical site infections, could not be 
analyzed thoroughly.
Renal retransplantation is a challenging surgical procedure with longer operative time, 
higher per-operative blood loss and a higher number of graft nephrectomies. In this 
series, retransplantation had no negative impact on patient survival as compared to 
a first transplant or to a second contralateral renal transplant. Regarding the patient 
survival benefits of having a functioning kidney allograft over being on dialysis, renal re-
transplantation should be tried as much as possible whenever clinical condition allows 
for it. Ipsilateral retransplantation seems to be associated to more operative complica-
tions and should therefore be reserved to the case where the patient is undergoing a 
third (and following) renal retransplantation where both iliac fossae have been surgi-
cally explored. Graft survival in case of a retransplant is lower than in first transplants 
and second contralateral transplants, mainly due to the higher rate of graft failures in 
the first year after kidney retransplantation. Most of these graft nephrectomies were 
necessary because of thrombotic events of the renal vessels. However, after the first 
few months the Kaplan-Meier graft survival curves were parallel. Preventing thrombotic 
events of the renal vessels in patients that receive a kidney retransplant in the ipsilateral 
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fossa, should be one of the main priorities in the postoperative care. Despite the above-
mentioned limitations, this case-controlled study provides an insight into the surgical 
challenges involving kidney retransplantation in the ipsilateral iliac fossa. This article 
provides transplant professionals a valid base to thoroughly inform patients who are 
considered for a kidney retransplant in the ipsilateral iliac fossa.
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Kidney transplantation is the best treatment for end stage renal disease and increases 
patient survival compared to dialysis. Due the continuing developments in the field of 
surgery and immunosuppressive therapy, kidney transplantation can be performed suc-
cesfully and nowadays may be offered to many patients with end stage renal disease. 
Since the 1950s, the surgical procedure includes placement of the transplant in the 
extraperitoneal iliac fossa, according to the so-called ‘Küss procedure’. Complications 
after kidney transplantation may be related to immunological or surgical events and 
both may comprise graft outcome. Reduction of surgical complications is still one of the 
challenges in kidney transplantation. We focused on urological complications after kid-
ney transplantation, including urinary leakage and ureteral strictures, both associated 
with significant morbidity, interventions, prolonged hospital stay and in a few cases, 
mortality. Most urological complications are related to the ureteroneocystostomy and 
optimizing the ureteral anastomosis is a main goal to improve the overall outcome of 
kidney transplantation.
In a previously conducted randomized controlled trial (INEX trial) we investigated the 
type of ureteral anastomosis (extravesical vs intravesical). No difference was observed in 
the number of urological complications between the intra- and extravesical anastomo-
sis, however, the number of urinary tract infections was lower in the extravesical group. 
Therefore, the extravesical anastomosis was chosen as the standard procedure for our 
surgical protocol. As the type of ureterovesical anastomosis did not influence the num-
ber of urological complications, our next aim was to investigate the relevance of using 
ureteral stents. To date 5, randomized controlled trials on stent placement have been 
reported. These studies differ in study design and include living as well as deceased do-
nation, intravesical and extravesical anastomosis and various types of stenting. Stenting 
seemed to be in favour, but it remained open for discussion whether this should be on 
routine basis or only on strictly defined criteria. A meta-analysis on this topic supports 
the use of ureteral stents in selected recipients, but a statement on routine stenting, 
type of stent and timing of stent removal is not available. Based on the preliminary 
results of a randomized controlled SPLINT trial (chapter 2) we tend to conclude that 
ureteral stent placement significantly reduces the number of PCN placements, urinary 
leakage and surgical re-interventions due to urological complications compared to no 
stent placement.
However, the type of stent remains a dispute. A Cochrane review debates which stent 
caliber and stent duration is best to avoid urological complications. Although the type 
of stent was mostly similar (double J stent was used in all but one study), the time until 
stent removal diverged from 7 days until 3 months and stent caliber varied from 5 to 7 
French (Fr) between all studies. Furthermore, most included studies were of retrospec-
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tive nature and included studies of an evidence level of 3. In our center, we prefer the 
use of external stents over double J stents, because of several advantages like the pos-
sibility of monitoring the grafts urine production and the simplicity of stent removal 
without a cystoscopy. In chapter 3, two different types of externalized ureteral stents are 
evaluated. Type A stenting refers to an 8 Fr ‘Covidien’ polyvinyl chloride tube and type 
B stenting refers to a 7 Fr polyurethane ‘Teleflex’ single J stent. We found a significantly 
higher incidence of urological complications in the group of patients receiving type A 
stenting and a higher incidence of rejection and urinary tract infections in the group 
receiving type B stenting.
Several risk factors are presumed to influence the number of urological complications 
after kidney transplantation, such as pre-emptive transplantations, male gender of re-
cipient and donor and the presence of multiple renal arteries. The native vascularization 
of the ureter is supplied by segmental arteries derived from the renal, vesicle, gonadal, 
common iliac or internal iliac vessels or directly from the abdominal aorta. During donor 
nephrectomy these segmental branches are dissected, resulting in the renal artery as 
the main blood supply of the ureter. Therefore, it can be hypothesized that a shorter 
ureteral length is accommodated with better vascularization and may possibly cause 
less urological complications. However, in chapter 4, we conclude that ureteral length 
does not influence the number of urological complications after kidney transplantation. 
More insight should be established in the microcirculation and perfusion of the ureteral 
blood flow. To our knowledge, only one animal study has shown that a ureteral access 
sheath can cause a transient decrease in ureteral blood flow. This raises the question 
whether the use of a ureterovesical stent in kidney transplantation influences the ureter 
microcirculation.
Ureteral obstruction is initially treated with a percutaneous nephrostomy (PCN). In many 
cases the obstruction will resolve spontaneously, but in a few cases additional treat-
ment is necessary. Treatment options for ureteral strictures include long term double J 
catheter insertion, balloon dilatation or surgical revision of the ureteroneocystostomy. 
In literature, only a few studies are available that report on the success-rate of these 
treatments. Balloon dilatation did prove its efficacy in the treatment of the ureterovesi-
cal junction for an obstructive mega-ureter and in uretero-ileal strictures of 1cm or less 
in patients after surgical urinary diversion. In chapter 5, a case series of fifty kidney 
transplant recipients who underwent antegrade balloon dilatation because of ureteral 
strictures is presented. In 7 patients, it was impossible to pass the strictured segment 
with the guidewire. In 20/43(47%) the procedure was clinically successful. Therefore, 
we believe that balloon dilatation should be advocated as the first treatment for ureter 
strictures, as it is less invasive than open surgical ureter reconstruction.
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Infectious complications may affect the recovery of patients receiving high-dose im-
munosuppressive therapy. The most commonly reported infectious complications 
after kidney transplantation are urinary tract infections. In chapter 6, we report that 
28% of patients developed a urinary tract infection within 3 months after transplanta-
tion. The most common causative agent was Escherichia coli, followed by Enterococcus 
faecalis and Klebsiella pneumoniae. The variables that were independently related to a 
urinary tract infection were female gender, recipients age above 60 years, percutaneous 
nephrostomy placement and surgical re-intervention. Mean glomerular filtration rate 
was significantly lower in the group of patients with a urinary tract infection at 3, 6, 9 
and 12 months postoperatively compared to those patients who did not have a urinary 
tract infection. In literature, incidence rates of 38% have been described and a relation 
between UTI and diminished graft function has been well described.
A less known complication after KT is incisional hernia. Incisional hernia is one of the most 
frequent postoperative complications after regular abdominal surgery. The incidence 
varies between 11 and 20% in general population. Known risk factors for development 
of incisional hernia are obesity, aneurysm of the abdominal aorta, immunosuppressive 
therapy, and postoperative wound infection. Hence, transplant recipients may have an 
increased risk to develop incisional hernia due to the use of postoperative immuno-
suppressive therapy resulting in impaired wound healing. The incidence of incisional 
hernia after kidney transplantation in literature, however, is reported to be remarkably 
low and varies between 1% and 7%. In chapter 8, we report an incidence of incisional 
hernia following kidney transplantation of 3.2%. We found obesity (BMI>30), female 
gender, concurrent abdominal wall hernias, history of smoking, duration of surgery, and 
multiple explorations to be independent risk factors for the development of incisional 
hernia after kidney transplantation.
Currently, 26% of patients on the Dutch kidney transplant waiting list awaits a retrans-
plant. Besides immunological difficulties, retransplantation may offer surgical challeng-
es. Several techniques for retransplantation have been described, including the trans-
peritoneal, retroperitoneal and orthotopic approach. As in most centers, we primarily 
implant the renal graft in the extraperitoneal iliac fossa. If a retransplantation must be 
performed, use of the contralateral iliac fossa is advocated. However, in case of a third or 
even fourth retransplant, it is unavoidable to explore an iliac fossa that has already been 
dissected for the previous implantation and for removal of the non-functioning graft. 
In chapter 9, ipsilateral retransplantations are compared to first transplants. Ipsilateral 
retransplantations had a longer operative time, higher per-operative blood loss and a 
higher number of graft nephrectomies. Graft survival in case of an ipsilateral retrans-
plant is lower than in first transplants and second contralateral transplants, mainly due 
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to the higher rate of graft failures in the first year after kidney retransplantation. Most 
of these graft nephrectomies were necessary because of thrombotic events of the renal 
vessels. This should be noticed and emphasized during the informed consent in case of 
patients that are planned or listed to receive an ipsilateral retransplant.
Conclusions and future perspectives
In this thesis, we have evaluated surgical complications that may occur after kidney trans-
plantation. We demonstrated that externalized ureteral stent placement significantly 
reduces urological complications, compared to not stenting the ureteral anastomosis. 
However, the type of stent is still under debate. Double J stenting seems to reduce the 
number of urological complications even more effectively, according current literature. 
Yet external stenting has several advantages like monitoring the grafts urine produc-
tion and the simplicity of stent removal without cystoscopy. Therefore, we suggest a 
randomized controlled trial between externalized stenting and the use of a double J 
stent, as suggested in chapter 7. In case of an externalized stent, we recommend a 7 
Fr polyurethane single J over an 8 Fr polyvinyl chloride straight tube, as it significantly 
reduced the number of urological complications in our retrospective cohort.
Furthermore, we have demonstrated that ureteral length does not influence the number 
of complications. It is of important for surgeons to realize that the vascularization of the 
ureter is fragile and gentle tissue handling is pivotal to prevent collateral damage to the 
microvessels in the ureter wall.
In case of a ureteral stricture, we recommend balloon dilatation as first treatment. Based 
on our data, this approach may be successful in 47% of the patients and it is less invasive 
than open surgical ureter reconstruction.
Urinary tract infections are a common problem after kidney transplantation. We have 
identified female gender, recipients age above 60 years, percutaneous nephrostomy 
placement and surgical re-intervention as risk factors. In our center, a urinary bladder 
catheter and an externalized stent are placed and removed on respectively day 7 and 
day 9 after transplantation, both without antibiotic prophylaxis. It may be advocated to 
remove the stent in patients with these risk factors protected by antibiotic prophylaxis, 
although there is no strong evidence for this approach. A well-designed prospective 
randomized controlled trial in KT recipients with an externalized stent could provide the 
answer to this issue.
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The incidence of incisional hernia following kidney transplantation is 3.2%. We found 
obesity (BMI>30), female gender, concurrent abdominal wall hernias, history of smok-
ing, duration of surgery, and multiple explorations to be independent risk factors for the 
development of incisional hernia after kidney transplantation. These risk factors should 
be considered when closing the fascia.
Ipsilateral retransplantation is associated with more operative complications and should 
therefore be reserved to the case where the patient is undergoing a third (and following) 
renal retransplantation where both iliac fossae have already been surgically explored. 
Regarding the patient survival benefits of having a functioning kidney allograft over 
being on dialysis, renal retransplantation is the best treatment option whenever the 
clinician condition of the recipients permits it. Graft survival in case of a retransplant 
is lower than in first transplants and second contralateral transplants. Most of these 
graft nephrectomies were necessary because of thrombotic events of the renal vessels. 
Preventing thrombotic events of the renal vessels in patients that receive a kidney 
retransplant in the ipsilateral fossa, should be one of the main priorities in the postop-
erative care. This should be noticed and emphasized during the informed consent in 
retransplant patients.

CHAPTER 11
Summary in English and Dutch
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This thesis describes surgical techniques used in kidney transplantation. Modifications 
that may minimize surgical complications and optimize outcome after kidney transplan-
tation are focus of the studies described.
In chapter 1 a historical overview of kidney failure and kidney transplantation is pre-
sented. Besides immunological challenges, surgical complications after kidney trans-
plantation can cause significant mortality, morbidity and result in graft loss. Common 
complications are related to the urological reconstruction where the new anastomosis 
between the graft ureter and the bladder of the recipients may lead to urinary leakage 
or ureteral stenosis. In addition, urinary tract infections may occur frequently. Prevent-
ing these surgical complications that comprise graft outcome, remains one of the chal-
lenges in kidney transplantation.
Chapter 2 describes the preliminary data of a randomized controlled trial performed 
in our center. This (SPLINT) trial compares the use of a suprapubic externalized stent 
with no stent placement during living donor kidney transplantations. Two hundred 
consecutive recipients were included in this trial between April 2014 and March 2017. 
The number of percutaneous nephrostomy placements within 1 month was defined as 
the primary outcome of this study. In the no stent group, there were significantly more 
PCN placements, more urinary leakages and surgical re-interventions due to urological 
complications. In the stent group, there were more patients with haematuria, graft rejec-
tion, and prolonged hospital stay. Mean GFR at day 7, 14, 21 and 1 month after trans-
plantation was equal in both groups. In a multivariate risk factor analyses, the variables 
that were independently related to PCN placement were no stent placement, a history 
of smoking and the first warm ischemia time. Therefore, we conclude that stenting the 
ureteral anastomosis should be advocated in living donor kidney transplant recipients.
In chapter 3, we describe results of a retrospective study in which we evaluated the 
influence of 2 different types of externalized ureteral stents (type A was an 8F polyvinyl 
chloride tube and type B was a 7F polyurethane single J stent) on the incidence of uro-
logical complications. We wondered whether one stent was superior to the other. We 
found a significantly higher incidence of PCN placements in patients who received the 
type A stent and a higher incidence of rejection and urinary tract infections in patients 
who received the type B stent. There were no significant differences in the reason for 
PCN placement or for patient or graft survival between both groups.
Several risk factors are presumed to influence the number of urological complications 
after kidney transplantation. During donor nephrectomy segmental branches of the 
native vascularization of the ureter are being dissected, leaving the renal artery as the 
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solitary blood supply of the ureter. Therefore, it can be hypothesized that a shorter ure-
teral length is accommodated with better vascularization and may cause less urological 
complications. This hypothesis was studied in chapter 4. Using data on the length of 
the ureter from the previously conducted randomized trial (INEX), we conclude that 
ureteral length does not influence the number of urological complications after kidney 
transplantation.
In chapter 5, we analyzed the outcome of balloon dilatation as treatment for ureter stric-
tures after kidney transplantation in a case series of 50 patients treated in the Erasmus 
University Medical Center and the Academic Medical Center. The technical success-rate 
was 86% and the subsequent clinical success-rate of balloon dilatation treatment 47%. 
We could not identify any factors that may have contributed to a (non)successful out-
come of a balloon dilatation. The length of the stenosis was not found to be predictive 
for the treatment outcome. We believe that balloon dilatation should be advocated 
as the first treatment for ureter strictures because it is less invasive than open surgical 
ureter reconstruction.
Chapter 6 includes the results of a retrospective study in which we analyzed the number 
of urinary tract infections that occur after kidney transplantation and its effect on graft 
function. We tried to identify risk factors for development of urinary tract infections. In 
this study, we identified 115 out of 417 patients (28%) who developed a urinary tract 
infection after kidney transplantation. In multivariate analysis, variables that were inde-
pendently related to the development of a urinary tract infection were female gender, 
recipients’ age>60y, PCN placement and surgical re-interventions within 3 months after 
transplantation. Mean GFR at 3, 6, 9 and 12 months after transplantation was signifi-
cantly lower in patients who had a urinary tract infection.
In current literature, there is no evidence whether external stenting or internal double 
J stenting is superior. In chapter 7, a new study protocol is proposed to assess if double 
J stenting of the ureteroneocystostomy during kidney transplantation is superior in 
preventing urological complications compared to externalized single J stenting. This will 
be a single-centre randomized controlled trial with a superiority design. All adult kidney 
transplant recipients (>18yrs) are invited to participate and in total 300 recipients will be 
included. The primary study outcome will be the number of percutaneous nephrostomy 
placements.
A less known complication after kidney transplantation is incisional hernia. Incisional 
hernia is one of the most frequent postoperative complications after regular abdominal 
surgery. Immunosuppressive therapy is a known risk factor for the development of 
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incisional hernia. Hence, transplant recipients may have an increased risk to develop 
incisional hernia. In chapter 8, we report an incidence of incisional hernia following 
kidney transplantation of 3.2%. We found obesity (BMI>30), female gender, concurrent 
abdominal wall hernias, history of smoking, duration of surgery, and multiple explo-
rations to be independent risk factors for the development of incisional hernia after 
kidney transplantation. These risk factors should be taken into account by surgeons, 
when closing the fascia.
As multiple explorations of a fossa is a risk factor for the development of incisional hernia, 
this may be an important issue as an increasing number of patients are listed to receive a 
retransplantation. In chapter 9, we present a retrospective case-controlled study on the 
surgical challenges of kidney retransplantation in the ipsilateral iliac fossa. Three control 
patients (first transplants) were matched to each study patient (ipsilateral retransplant). 
We showed that operative time and intra-operative estimated blood loss are significantly 
higher in patients that received a retransplant in the ipsilateral iliac fossa. Furthermore, 
patients with a retransplant have a significantly higher risk for thrombotic events of the 
renal vessels. The number of urological complications was not higher. The rate of graft 
nephrectomies performed in the first year after transplantation was significantly higher 
in the study group then in the control group, with 16% vs 5%, respectively. The overall 
graft survival was lower in the study group, however patient survival was not affected by 
the number of transplantations.
In chapter 10, the studies performed in chapter 2 until 9 are discussed and ideas for 
future studies that may address remaining questions are presented.

Summary in English and Dutch 135
11
Samenvatting
Dit proefschrift beschrijft de chirurgische technieken die worden uitgevoerd tijdens 
niertransplantaties. Wij hebben onderzoek gedaan naar manieren om chirurgische 
complicaties te minimaliseren en het resultaat na niertransplantatie te optimaliseren.
In hoofdstuk 1 wordt een historisch overzicht gegeven van nierfalen en niertransplan-
tatie. Naast immunologische uitdagingen die een rol spelen bij niertransplantaties, 
kunnen ook chirurgische complicaties voor significante mortaliteit en morbiditeit 
zorgen en zelfs tot transplantaat verlies leiden. De meest bekende chirurgische com-
plicaties na niertransplantatie zijn de urologische complicaties. Dit zijn complicaties die 
zich afspelen rondom de nieuwe aansluiting tussen de donor urineleider en de blaas 
van de ontvanger, zoals urinelekkage of vernauwingen van de urineleider. Andere 
complicaties die rondom de transplantatie kunnen voorkomen zijn infecties, waarvan 
de urineweginfectie de meest voorkomende is. Het voorkomen van deze chirurgische 
complicaties die tot transplantaat verlies kunnen leiden, blijft een van de uitdagingen 
bij niertransplantaties.
Hoofdstuk 2 beschrijft de voorlopige resultaten van een gerandomiseerd en gecontro-
leerd onderzoek, dat in ons centrum werd uitgevoerd. Deze (SPLINT) trial vergelijkt het 
gebruik van een suprapubisch geëxternaliseerde stent met het niet plaatsen van een 
stent bij niertransplantaties van levende donoren. Tweehonderd opeenvolgende nier 
ontvangers namen deel aan dit onderzoek, tussen april 2014 en maart 2017. Percutane 
nefrostomie plaatsing binnen 1 maand was de primaire uitkomstmaat van deze studie. 
In de geen-stent-groep waren er aanzienlijk meer percutane nefrostomie plaatsingen, 
urine lekkages en chirurgische re-interventies als gevolg van urologische complicaties. In 
de stent-groep waren er meer patiënten met hematurie, afstoting van het transplantaat 
en deze groep was langer opgenomen in het ziekenhuis na de transplantatie. De gemid-
delde GFR op dag 7, 14, 21 en 1 maand na transplantatie was gelijk in beide groepen. 
In een multivariate risicofactor analyse waren: geen stent plaatsing, roken (of vroeger 
roken) en de eerste warme ischemie tijd onafhankelijk verbonden met PCN-plaatsing. 
Daarom moet de nieuwe anastomose tussen urineleider en blaas gestent worden bij 
niertransplantaties van levende donoren.
In hoofdstuk 3 beschrijven we de resultaten van een retrospectieve studie. In dit onder-
zoek hebben we 2 verschillende types geëxternaliseerde stents met elkaar vergeleken. 
Type A was een 8 french polyvinylchloride stent en type B een 7 french polyurethaan 
stent met een krul aan de tip. We vonden een significant hogere incidentie van PCN-
plaatsingen in patiënten met het type A-stent en meer afstotingen en urineweginfecties 
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bij patiënten die het type B-stent kregen. Er waren geen significante verschillen in de 
reden voor het plaatsen van een PCN. Ook vonden we geen verschillen in mortaliteit en 
transplantaat-overleving tussen beide groepen.
Er zijn verschillende factoren bekend die het risico op urologische complicaties na 
niertransplantatie vergroten. Gedurende de donor nefrectomie worden de segmentale 
takken van de oorspronkelijke vascularisatie van de urineleider doorgenomen. Dit zorgt 
ervoor dat de nier arterie als enige bloedtoevoer van de urineleider fungeert. Daarom 
kan worden verondersteld dat een kortere urineleider gepaard gaat met een betere 
vascularisatie en mogelijk met minder urologische complicaties. In hoofdstuk 4 conclu-
deren we echter dat de lengte van de urineleider het aantal urologische complicaties na 
niertransplantatie niet beïnvloedt. Voor deze analyse hebben we de gegevens van een 
eerder uitgevoerde gerandomiseerde trial (INEX) gebruikt.
In hoofdstuk 5 analyseerden we het effect van ballondilataties (dotterprocedures) als 
behandeling voor vernauwingen in de urineleider na niertransplantaties. Deze serie 
bestaat uit 50 patiënten die behandeld zijn in het Erasmus Universitair Medisch Cen-
trum en het Academisch Medisch Centrum. Het was technisch succesvol in 86% van de 
patiënten en het daaropvolgende klinische succes was 47%. We konden geen factoren 
identificeren die van te voren konden voorspellen of de dotterbehandeling zinvol zou 
zijn of niet. Wij zijn van mening dat de ballondilatatie de eerste behandelkeus moet zijn 
bij patiënten met vernauwingen in de urineleider, omdat het minder invasief is dan een 
chirurgische correctie.
Hoofdstuk 6 bevat de resultaten van een retrospectieve studie waarin we het aantal uri-
neweginfecties na niertransplantatie analyseerden. Daarnaast hebben we geprobeerd 
risicofactoren voor het ontwikkelen van urineweginfecties te identificeren. Er bleken 115 
van de 417 patiënten (28%) een urineweginfectie te ontwikkelden na niertransplantatie. 
In een multivariate analyse waren de variabelen die onafhankelijk verband hielden met 
het ontwikkelen van een urineweginfectie de volgende: vrouwelijk geslacht, leeftijd van 
de ontvangers> 60 jaar, PCN-plaatsing en chirurgische re-interventies binnen 3 maan-
den na transplantatie. De gemiddelde GFR op 3, 6, 9 en 12 maanden na transplantatie 
was significant lager bij patiënten die een urineweginfectie hadden doorgemaakt.
In de huidige literatuur is er geen sluitend bewijs dat de dubbel J stent beter is dan 
de externe stent. In hoofdstuk 7 stellen we een nieuw onderzoeksprotocol voor. In dit 
onderzoek willen we beoordelen of de dubbel J stent beter is dan de suprapubisch 
geëxternaliseerde stent in het voorkomen van urologische complicaties na niertrans-
plantaties. Dit onderzoek zal worden uitgevoerd in het Erasmus MC en zal een zogehe-
Summary in English and Dutch 137
11
ten ‘superiority design’ hebben. Alle niertransplantatie ontvangers (> 18 jaar) worden 
uitgenodigd om deel te nemen aan dit onderzoek. In totaal willen we 300 ontvangers 
in deze studie includeren. De primaire uitkomstmaat van dit onderzoek zal het aantal 
percutane nefrostomie plaatsingen zijn.
Een minder bekende complicatie na niertransplantatie is een littekenbreuk. Litteken-
breuken zijn echter wel een van de meest voorkomende complicaties na reguliere 
buikoperaties. Immunosuppressieve medicatie is een bekende risicofactor voor het ont-
wikkelen van een littekenbreuk. Daarom kunnen transplantatiepatiënten een verhoogd 
risico hebben om een littekenbreuk te ontwikkelen. In hoofdstuk 8 rapporteren we een 
incidentie van 3.2% littekenbreuken na niertransplantaties. We hebben een aantal risi-
cofactoren gevonden die de kans op een littekenbreuk doen toenemen. Dit zijn obesitas 
(BMI> 30), het vrouwelijk geslacht, gelijktijdige andere buikwand hernia’s, roken (of in 
het verleden gerookt), duur van de operatie en meerdere operaties via dezelfde incisie. 
Deze risicofactoren moet door de operateur worden meegenomen als ze de fascie 
sluiten.
Het vaker opereren via dezelfde incisie geeft dus een verhoogd risico op een litteken 
breuk. Dit zal dus in de toekomst mogelijk een groter probleem worden omdat steeds 
meer patiënten op de wachtlijst staan om een re-transplantatie te ondergaan. In 
hoofdstuk 9 presenteren we een retrospectieve case-control studie over de chirurgische 
uitdagingen van niertransplantatie in een al eerder gebruikte fossa. Drie controle pa-
tiënten (eerste transplantaties) werden gematcht aan elke studie patiënt (ipsilaterale 
re-transplantatie). We laten in dit onderzoek zien dat de operatieduur langer en het 
bloedverlies significant hoger is bij patiënten die een re-transplantatie ondergaan. 
Bovendien hebben patiënten met een re-transplantaat een significant hoger risico op 
een trombotisch event van de vaten van het niertransplantaat. Het aantal urologische 
complicaties was niet groter. In het eerste jaar na transplantatie is het aantal verwijderde 
transplantaten in de studie groep aanzienlijk hoger dan in de controle groep, respec-
tievelijk 16% versus 5%. De transplantaat-overleving was lager in de studie groep ten 
opzichte van de controle groep, maar de patiënt-overleving werd niet beïnvloed door 
het aantal transplantaties.
In hoofdstuk 10 worden de onderzoeken van hoofdstuk 2 tot en met 9 besproken en 
suggesties voor toekomstig onderzoek worden gegeven.
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Na 3,5 jaar is het eindelijk zover, mijn proefschrift is af. Dit proefschrift is tot stand 
gekomen door de hulp van een groot team. Ik wil dus ook iedereen bedanken die mij 
hiermee heeft geholpen. Er zijn een aantal mensen die ik in het bijzonder wil benoemen.
Beste professor Ijzermans, mijn promotor. Bedankt voor het vertrouwen wat ik van u 
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Ik ben erg benieuwd naar de uitkomsten. U heeft me de afgelopen jaren veel geleerd en 
u gaf me de ruimte om me zowel op wetenschappelijk als persoonlijk gebied verder te 
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Beste Turkan, mijn copromotor. Bedankt voor de vrijheid die je me gaf als ik weer eens 
met een nieuw idee kwam, wat ik vaak dan ook mocht uitvoeren. Ik ben er trots op dat 
we de SPLINT trial met veel succes hebben afgerond en het volgende onderzoeksvoor-
stel al klaar ligt. Je met de hand gecorrigeerde artikelen, ga ik nog missen. Bedankt voor 
je eeuwige kritische blik en inzet voor mijn promotie.
Beste professor Zietse, de secretaris van mij leescommissie. Hartelijk dank voor het 
beoordelen van mijn proefschrift. Ik kijk nog altijd met een lach terug naar mijn master-
onderzoek, waarbij u me heeft begeleid in het onderzoek naar de invloed van cisplatine 
op de magnesium huishouding.
Beste overige leescommissie leden, professor Alwayn en professor Hilbrands, zeer veel 
dank voor het beoordelen van mijn proefschrift en uw waardevolle bijdragen. Tevens 
wil ik mijn overige opponenten bedanken voor hun bereidheid om zitting te nemen in 
mijn commissie.
Verder wil ik de 200 deelnemers van de SPLINT trial bedanken voor de genomen tijd en 
moeite om deel te nemen. Zonder uw waardevolle bijdragen aan dit onderzoek, zou dit 
proefschrift er niet zijn geweest.
Beste Diederik, Frank, Khe, Hermien, Robert, Kelly en Ellen bedankt voor jullie hulp tijd 
en vooral geduld tijdens de uitvoering van de SPLINT trial. Dagelijks kreeg ik van jullie 
een appje dat er ge-TOP-t was, waarop ik snel met het lootje jullie kant op kon. Beste 
Diederik, ik heb veel van je geleerd, waarbij ik met name altijd onder de indruk was van 
hoe jij met patiënten communiceert en veel hart voor de zaak hebt. Naast de vele uren 
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op de poli, hebben we er ook genoeg samen doorgebracht aan de bar op congressen 
en wintersport. Je bent altijd bereid geweest met me mee te denken op persoonlijk en 
wetenschappelijk aspect en dat stel ik ontzettend op prijs. Beste Frank, nu ondertus-
sen al een tijd in Londen, maar ook zeker nauw betrokken geweest met het tot stand 
komen van dit proefschrift. Ons uitstapje naar de mircoRNAS in nierperfusaten is nog 
niet zo een succes als we hoopten, wellicht komt dat nog in een later stadium. Jij ook 
bedankt voor de leuke tijd op de OK, de zangsessies tijdens de LIDO en de late uurtjes op 
congressen. Beste Khe, geen splint of wel een splint, het was altijd wat jij nét niet wilde. 
Bedankt dat je me de mogelijkheid hebt gegeven om naast mijn promotie me ook te 
ontwikkelen op persoonlijk vlak met de organisatie van de chirurgencup. Hopelijk lukt 
het volgend jaar om wel die cup weer mee naar Rotterdam te nemen. Beste Hermien 
en Robert, beiden zijn jullie meer betrokken geraakt in een later stadium van mijn 
onderzoeksperiode, maar absoluut even waardevol. Ook jullie hebben mij geholpen en 
gesteund en wilden altijd meedenken over verbetering, waarvoor heel veel dank. Lieve 
Kelly en Ellen, bedankt voor onze leuke tijd samen.
Beste nefrologen, ook jullie hartelijk dank voor het meedenken en natuurlijk voor de 
nauwkeurige follow up van de niertransplantatie patiënten, waardoor dit onderzoek 
mogelijk is geworden.
Beste co-auteurs, bedankt voor jullie kritische blikken, tips en aanvullingen op mijn 
manuscripten.
Mijn paranimfen verdienen ook een bijzondere vermelding, kamertje 1 bravo. Beste 
Joost, alweer een jaar geleden mocht ik vol trots aan jouw zijde pronken als paranimf en 
ik waardeer het enorm dat je het nu ook andersom wilt doen. Onze tijd begon samen in 
traumacentrum IJsselland in 2012. Een half jaar na jou, kon ik ook in de Z-flat beginnen, 
waar jij al snel een plekje voor me had gereserveerd in kamertje 1. Ondertussen ben jij 
al een jaar in opleiding en spreken we elkaar niet meer dagelijks helaas, desalniettemin 
ben je voor mij een steun geweest tijdens alle lange uurtjes op de 8ste, bedankt hiervoor. 
Lieve Marcia, lekkere Eskimo, jij kwam in het mooiste kamertje in het najaar van 2014. Je 
moest aan het begin even wennen aan de danssessies op stoelen van mij en Joost, maar 
al snel bracht je Taylor Swift in en konden we gewoon lekker samen feesten. Ik mis onze 
app sessies als Shanaisha en Karishma, jammer dat je je telefoonnummer aan het einde 
moest veranderen. Ook ons concert met JB was natuurlijk the bomb, ‘sorry’.
Lieve overige Z-buddies, lieve Gulia, bedankt voor de leuke tijd in onze kamer, ondanks 
dat jouw hart misschien bij de MDL lag, was je absoluut kamertje 1 waardig ;) Lieve Mus, 
fietsmaatje, bedankt voor de lange gesprekken en adviezen. Lieve Annie, mijn renmaatje, 
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mooiste studentenverenging, ik heb van je genoten. Overige Z-flatters, traumajongens, 
Danielers en Lablui, hartelijk dank voor de leuke tijd en gezelligere borrels. Hou vol ook 
voor jullie komt dit moment.
Lieve IJsvogels, bedankt voor de ontzettend leuke tijd en steun tijdens mijn ‘lange pro-
motie onderzoek’. Jullie zijn allemaal van de categorie; ‘been there, done that’ en wisten 
precies wat ik meemaakte.
Beste Maasstad-ers, na al die jaren onderzoek was de overstap naar de kliniek weer even 
wennen. Bedankt voor jullie steun en gezelligheid in de afgelopen maanden.
Beste Carola, jij hebt geen idee hoeveel je voor de transplantatie sector betekend. Ik 
snap dat het even wennen was voor iedereen, toen jij overstapte naar het onderzoeks-
bureau. Bedankt voor al jouw hulp, ik zou niet weten wat ik zonder je had gemoeten.
Lieve vrienden en vriendinnen, medisch en niet medisch. Jullie gezelligheid heeft de 
afgelopen jaren makkelijker gemaakt voor mij. Ik kon altijd op jullie bouwen voor steun 
in de vorm van een drankje en een lekker hapje. Ik ben blij dat ik al mijn ontwikkelingen 
met jullie heb kunnen delen en ik kijk ernaar uit om weer meer tijd te hebben voor een 
borrel, feestje of uitstapje.
Lieve familie, we zijn er altijd voor elkaar en ik kan altijd op jullie rekenen. Bedankt voor 
jullie luisterende oor als het weer eens tegenzat en jullie betrokkenheid bij mijn promo-
tieonderzoek! Ik verheug me erop dat ik straks weer meer tijd heb voor kaasplanken, 
Franse wijn en Elbmeister! Ik hou van jullie.
Lieve Guid, onwijze pitbull van me, wat ben ik blij dat jij een doorzetter bent. We hebben 
elkaar ontmoet tijdens mijn promotie en wonen nu alweer een half jaar samen. Bedankt 
voor je steun, interesse en het meedenken. Dankzij jou maak ik eindelijk wat stappen de 
juiste kant op. Ik zal jou ook helpen bij de laatste loodjes als jouw proefschrift aan het 
einde komt. Ik ben stapelgek op je.
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